DDI-DrugBank.d68.s4	Calcium_channel_blocking_agents NNS B-noun.artifact	, , 0	Coadministration NNP B-noun.person	of IN I-noun.person	calcium_channel_blockers NNS I-noun.person	did VBD 0	not RB B-adv.all	have VB B-verb.change	any DT 0	effect NN B-noun.cognition	on IN 0	either CC 0	the DT 0	safety NN B-noun.artifact	or CC 0	efficacy NN B-noun.phenomenon	of IN 0	ibutilide NN B-noun.food	in IN 0	the DT 0	clinical JJ B-adj.all	trials NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d284.s6	BROVANA NNP B-noun.group	, , 0	as IN 0	with IN 0	other JJ B-adj.all	beta2-agonists NNS B-noun.person	, , 0	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	extreme JJ B-adj.all	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	being VBG 0	treated VBN B-verb.change	with IN 0	monoamine_oxidase_inhibitors NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	or CC 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	prolong VB B-verb.stative	the DT 0	QTc NNP B-noun.person	interval NN I-noun.person	because IN 0	the DT 0	action NN B-noun.process	of IN 0	adrenergic_agonists NNS B-noun.person	on IN 0	the DT 0	cardiovascular JJ B-adj.all	system NN B-noun.substance	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	these DT 0	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d171.s3	Interaction NN 0	with IN 0	phenytoin NN B-noun.person	, , 0	lidocaine NN B-noun.person	and CC 0	theophylline PRP 0	has VBZ 0	also RB B-adv.all	been VBN 0	reported VBN B-verb.communication	to TO 0	produce VB B-verb.change	adverse JJ B-adj.all	clinical JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d308.s3	Patients NNS B-noun.person	should MD 0	be VB 0	advised VBN B-verb.communication	against IN 0	the DT 0	simultaneous JJ B-adj.all	use NN B-noun.act	of IN 0	other JJ B-adj.all	CNS_depressant_drugs NNS B-noun.object	, , 0	and CC 0	cautioned VBD B-verb.communication	that IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	alcohol NN B-noun.animal	may MD 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d233.s3	Use NN 0	with IN 0	Angiotensln_Converting_Enzyme_Inhibitors NNS B-noun.person	, , 0	The DT 0	use NN 0	of IN 0	angiotensin_converting_enzyme_inhibitors NNS 0	to TO 0	control VB B-verb.social	hypertension NN B-noun.act	in IN 0	patients NNS B-noun.person	on IN 0	azathioprine NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	induce VB B-verb.cognition	severe JJ B-adj.all	leukopenia NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d89.s6	Interconversion NN 0	between IN 0	caffeine NN B-noun.person	and CC 0	theophylline PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	preterm JJ B-adj.all	neonates NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d318.s1	Antineoplastic_agents NNS B-noun.relation	( ( 0	e. FW 0	g. FW 0	, , 0	nitrogen_mustard RB 0	, , 0	etc FW 0	. . 0	) ) 0	should MD 0	be VB 0	given VBN B-verb.possession	concomitantly RB B-adv.all	only RB B-adv.all	with IN 0	great JJ B-adj.all	caution NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d562.s10	Seizures NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	another DT 0	quinolone_class_antimicrobial JJ B-noun.other	and CC 0	the DT 0	nonsteroidal_anti JJ B-noun.group	- : 0	inflammatory_drug NN B-noun.person	fenbufen NN B-noun.person	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d246.s10	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	a DT 0	1-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	butorphanol NN 0	administered VBN B-verb.possession	as IN 0	STADOL_NS NNS B-noun.group	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	cimetidine NN B-noun.phenomenon	( ( 0	300 CD 0	mg IN 0	QID NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d82.s28	It PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that IN 0	the DT 0	addition NN B-noun.act	of IN 0	triamterene NN B-noun.person	to TO 0	a DT 0	maintenance NN B-noun.person	schedule NN B-noun.person	of IN 0	INDOCIN NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	reversible JJ B-adj.all	acute JJ B-adj.all	renal JJ B-adj.all	failure NN B-noun.person	in IN 0	two CD 0	of IN 0	four CD 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d113.s3	In IN 0	addition NN 0	to TO 0	this DT 0	pharmacological JJ B-adj.all	interaction NN B-noun.act	, , 0	this DT 0	report NN B-noun.communication	describes VBZ B-verb.communication	a DT 0	novel JJ B-adj.all	chemical NN B-noun.process	reaction NN B-noun.process	between IN 0	temazepam NN B-noun.person	( ( 0	a DT 0	benzodiazepine NN 0	) ) 0	and CC 0	ethanol NN B-noun.act	under IN 0	acidic JJ B-adj.all	conditions NNS B-noun.event	similar JJ 0	to TO 0	those DT 0	found VBN B-verb.perception	in IN 0	vivo NN B-noun.animal	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	3-ethoxylated JJ B-adj.all	product NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d269.s13	Therefore RB 0	, , 0	increased VBD B-verb.change	monitoring NN B-noun.person	of IN 0	digoxin NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	initiating VBG B-verb.communication	, , 0	adjusting NN B-verb.change	, , 0	or CC 0	discontinuing VBG B-verb.change	COREG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d219.s24	There EX 0	was VBD B-verb.stative	no DT 0	significant JJ B-adj.all	difference NN B-noun.cognition	in IN 0	the DT 0	pharmacodynamic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.person	administered VBD B-verb.perception	alone RB B-adv.all	and CC 0	warfarin NN B-noun.act	administered VBN B-verb.possession	with IN 0	Lodine NNP B-noun.person	as IN 0	measured VBN B-verb.cognition	by IN 0	prothrombin NN B-noun.person	time NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d367.s3	Doxazosin_mesylate NN B-noun.group	has VBZ 0	been VBN 0	administered VBN B-verb.perception	without IN 0	any DT 0	evidence NN B-noun.attribute	of IN 0	an DT 0	adverse JJ B-adj.all	drug NN B-noun.artifact	interaction NN 0	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	thiazide_diuretics NNS B-noun.person	, , 0	beta JJ 0	- : 0	blocking_agents NNS B-noun.person	, , 0	and CC 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d198.s31	When WRB 0	Vardenafil NNP B-noun.person	dosing NN B-verb.social	was VBD 0	separated VBN B-verb.contact	from IN 0	terazosin NN B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	by IN 0	6 CD B-adj.all	hours NNS B-noun.person	, , 0	7 CD 0	of IN 0	28 CD B-adj.all	subjects NNS B-noun.person	who WP 0	received VBD B-verb.possession	20 CD B-adj.all	mg NN B-noun.quantity	of IN 0	Vardenafil NNP B-noun.person	experienced VBD B-verb.perception	a DT 0	decrease NN B-noun.event	in IN 0	standing VBG B-verb.contact	systolic JJ B-adj.all	blood NN B-noun.group	pressure NN B-noun.person	below IN 0	85 CD 0	mm NN B-noun.quantity	Hg NNP 0	. . 0	. . 0
DDI-MedLine.d116.s3	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	rifampin NN B-noun.communication	and CC 0	warfarin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	the DT 0	need NN B-noun.object	for IN 0	an DT 0	unusually RB B-adj.all	high JJ B-adj.all	maintenance NN B-noun.phenomenon	dose NN B-noun.quantity	of IN 0	warfarin NN B-noun.substance	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	per IN 0	day NN B-noun.animal	) ) 0	in IN 0	order NN 0	to TO 0	produce VB B-verb.creation	a DT 0	therapeutic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d523.s1	Interactions NNS 0	attributed VBN 0	to TO 0	the DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	baclofen JJ B-adj.all	injection NN B-noun.act	and CC 0	epidural JJ B-adj.all	morphine NN B-noun.person	include VBP B-verb.change	hypotension NN B-noun.attribute	and CC 0	dyspnea NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s5	Clinical JJ B-adj.all	studies NNS B-noun.communication	have VBP 0	shown VBN B-verb.cognition	that IN 0	INDOCIN NNP B-noun.group	does VBZ 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	hypoprothrombinemia NN 0	produced VBN B-verb.creation	by IN 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d561.s0	Diuretics NNS B-noun.person	, , 0	Patients NNPS B-noun.person	on IN 0	diuretics NNS B-noun.person	, , 0	especially RB B-adv.all	those DT 0	in IN 0	whom WP 0	diuretic JJ B-adj.all	therapy NN B-noun.act	was VBD B-verb.stative	recently RB B-adv.all	instituted VBN B-verb.communication	, , 0	may MD 0	occasionally RB 0	experience VB B-verb.social	an DT 0	excessive JJ B-adj.all	reduction NN B-noun.process	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	after IN 0	initiation NN B-noun.time	of IN 0	therapy NN 0	with IN 0	Lotensin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d397.s3	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	increased VBN B-verb.change	anticoagulant JJ B-adj.all	effects NNS B-noun.phenomenon	when WRB 0	erythromycin NN B-noun.person	and CC 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	were VBD 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d414.s0	Lithium NNP B-noun.person	generally RB I-noun.person	should MD 0	not RB 0	be VB 0	given VBN B-verb.possession	with IN 0	diuretics NNS B-noun.person	because IN 0	they PRP 0	reduce VBP B-verb.change	its PRP$ 0	renal JJ B-adj.all	clearance NN B-noun.act	and CC 0	add VB B-verb.communication	a DT 0	high JJ B-adj.all	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d440.s0	Calcium NNP B-noun.other	Supplements NNPS I-noun.other	/ POS I-noun.other	Antacids NNPS I-noun.other	. . 0
DDI-DrugBank.d249.s13	A DT 0	direct JJ B-adj.all	causal NN B-adj.all	relationship NN B-noun.state	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	, , 0	but CC 0	physicians NNS B-noun.person	should MD 0	consider VB B-verb.communication	the DT 0	possibility NN B-noun.state	that IN 0	diclofenac NN B-noun.person	may MD 0	alter VB B-verb.change	a DT 0	diabetic JJ B-noun.person	patient NN B-noun.person	s IN 0	response NN B-noun.communication	to TO 0	insulin VB B-verb.contact	or CC 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d232.s1	The DT 0	similarity NN B-noun.attribute	of IN 0	the DT 0	TYSABRI NNP B-noun.group	-associated VBD B-verb.stative	adverse JJ B-adj.all	event NN 0	profile NN B-noun.communication	between IN 0	Study NNP B-noun.communication	1 CD 0	( ( 0	without IN 0	co SYM 0	- : 0	administered VBN B-verb.communication	AVONEX NNP B-noun.group	) ) 0	and CC 0	Study NNP B-noun.communication	2 CD 0	( ( 0	with IN 0	co SYM 0	- : 0	administered VBN B-verb.communication	AVONEX NNP B-noun.group	) ) 0	indicates VBZ B-verb.communication	that IN 0	this DT 0	alteration NN B-noun.cognition	in IN 0	clearance NN 0	does VBZ 0	not RB B-adv.all	necessitate JJ B-adj.all	reduction NN B-noun.process	of IN 0	the DT 0	TYSABRI NNP B-noun.group	_ POS 0	dose NN B-noun.quantity	to TO 0	maintain VB B-verb.consumption	safety NN I-verb.consumption	, , 0	General NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d325.s7	Butyrophenones NNS 0	( ( 0	such JJ 0	as IN 0	haloperidol NN 0	) ) 0	and CC 0	phenothiazines NNS B-noun.person	can MD 0	suppress VB B-verb.social	the DT 0	dopaminergic JJ B-adj.all	renal JJ B-noun.body	and CC 0	mesenteric JJ B-adj.all	vasodilation NN B-noun.communication	induced VBN B-verb.creation	with IN 0	low JJ B-adj.all	dose NN 0	dopamine NN 0	infusion NN 0	. . 0	. . 0
DDI-DrugBank.d175.s14	Potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.group	such JJ 0	as IN 0	spironolactone NN 0	, , 0	triamterene NN B-noun.person	, , 0	or CC 0	amiloride VB B-verb.social	, , 0	or CC 0	potassium NN B-noun.artifact	supplements NNS B-noun.artifact	should MD 0	be VB 0	given VBN B-verb.possession	only RB B-adv.all	for IN 0	documented VBN B-verb.consumption	hypokalemia NN I-verb.consumption	, , 0	and CC 0	then RB B-adv.all	with IN 0	caution NN B-noun.cognition	, , 0	since IN 0	they PRP 0	may MD 0	lead VB B-verb.cognition	to TO 0	a DT 0	significant JJ B-adj.all	increase NN B-noun.event	of IN 0	serum NN B-noun.person	potassium NN B-noun.person	. . 0	. . 0
DDI-MedLine.d14.s1	It PRP 0	was VBD 0	established VBN B-verb.cognition	that IN 0	both DT 0	angiotensins NNS B-noun.person	inhibited VBN B-verb.change	gastric JJ B-adj.all	acid NN 0	secretion NN 0	stimulated VBN B-verb.communication	by IN 0	pentagastrin NN B-noun.person	but CC 0	not RB B-adv.all	by IN 0	histamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d175.s0	Hypotension NNP B-noun.person	__ POS 0	Patients NNPS B-noun.person	on IN 0	Diuretic NNP B-noun.person	Therapy NNP I-noun.person	, , 0	Patients NNPS B-noun.person	on IN 0	diuretics NNS B-noun.person	and CC 0	especially RB B-adv.all	those DT 0	in IN 0	whom WP 0	diuretic JJ B-adj.all	therapy NN B-noun.act	was VBD B-verb.stative	recently RB B-adv.all	instituted VBN B-verb.communication	, , 0	as RB 0	well RB 0	as IN 0	those DT 0	on IN 0	severe JJ B-adj.all	dietary JJ B-adj.all	salt NN B-noun.food	restriction NN B-noun.act	or CC 0	dialysis NN B-noun.substance	, , 0	may MD 0	occasionally RB 0	experience VB B-verb.change	a DT 0	precipitous JJ B-adj.all	reduction NN B-noun.act	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	usually RB B-adv.all	within IN 0	the DT 0	first JJ B-adj.all	hour NN B-noun.communication	after IN 0	receiving VBG B-verb.communication	the DT 0	initial JJ B-adj.all	dose NN B-noun.act	of IN 0	captopril NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d87.s20	There EX 0	has VBZ 0	been VBN B-verb.stative	too RB B-adv.all	little JJ B-adj.all	experience NN B-noun.person	with IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	TAMBOCOR NNP 0	with IN 0	nifedipine NN B-noun.person	or CC 0	diltiazem VB B-verb.change	to TO 0	recommend VB B-verb.communication	concomitant JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d388.s0	Catecholamine SYM 0	- : 0	depleting_drugs NNS B-noun.time	, , 0	such JJ 0	as IN 0	reserpine NN B-noun.person	, , 0	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	beta JJ B-noun.body	- : 0	blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d543.s2	Anticholinergics NNS B-noun.person	antagonize VBP B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	antiglaucoma_agents NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d393.s2	In IN 0	a DT 0	multiple JJ B-adj.all	dose NN B-noun.act	study NN B-noun.artifact	of IN 0	theophylline PRP 0	( ( 0	400 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	3 CD B-adj.all	days NNS B-noun.artifact	) ) 0	and CC 0	cetirizine NN B-noun.location	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	3 CD B-adj.all	days NNS B-noun.artifact	) ) 0	, , 0	a DT 0	16 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	the DT 0	clearance NN B-noun.act	of IN 0	cetirizine NN B-noun.location	was VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d220.s4	Because IN 0	of IN 0	the DT 0	danger NN B-noun.person	of IN 0	a DT 0	potentially RB B-adv.all	fatal JJ B-adj.all	prolongation NN B-noun.act	of IN 0	the DT 0	QTc NNP B-noun.person	interval NN I-noun.person	, , 0	halofantrine NN B-noun.person	must MD 0	not RB 0	be VB 0	given VBN B-verb.possession	simultaneously RB B-adv.all	with IN 0	or CC 0	subsequent JJ B-adj.all	to TO 0	Mefloquine NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d10.s2	Betaseron NNP B-noun.person	administration NN I-noun.phenomenon	to TO 0	three CD 0	cancer NN B-adj.all	patients NNS B-noun.person	over IN 0	a DT 0	dose JJ B-adj.all	range NN B-noun.location	of IN 0	0.025 CD 0	mg NN B-noun.quantity	to TO 0	2.2 CD 0	mg NNS B-noun.quantity	led VBN B-verb.stative	to TO 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	antipyrine JJ B-noun.person	elimination.14 NNP I-noun.person	The DT I-noun.person	effect NN I-noun.person	of IN 0	alternate JJ B-adj.all	- : 0	day NN 0	administration NN 0	of IN 0	0.25 CD 0	mg NN B-noun.quantity	of IN 0	Betaseron NNP B-noun.person	on IN 0	drug NN B-noun.artifact	metabolism NN B-noun.artifact	in IN 0	MS NNP 0	patients NNS B-noun.person	is VBZ B-verb.stative	unknown JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d176.s3	Potassium NNP B-noun.person	Supplements NNPS I-noun.person	and CC 0	Potassium NNP B-noun.person	- : 0	Sparing_Diuretics NNS B-noun.person	, , 0	Fosinopril_sodium NN 0	can MD 0	attenuate VB B-verb.social	potassium NN 0	loss NN 0	caused VBN B-verb.communication	by IN 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d64.s4	Chloral_hydrate NN B-noun.artifact	may MD 0	cause VB B-verb.communication	an DT 0	increased JJ B-adj.all	prothrombin NN B-noun.person	response NN B-noun.communication	by IN 0	displacing VBG B-verb.communication	the DT 0	anticoagulant NN B-noun.attribute	from IN 0	protein NN B-noun.animal	binding JJ B-verb.contact	sites NNS B-noun.state	or CC 0	a DT 0	diminished JJ B-adj.all	prothrombin NN B-noun.person	response NN B-noun.communication	through IN 0	increased VBN B-verb.change	metabolism NN B-noun.attribute	of IN 0	the DT 0	unbound JJ B-adj.all	drug NN B-noun.person	by IN 0	hepatic JJ B-adj.all	enzyme NN B-noun.phenomenon	induction NN I-noun.phenomenon	, , 0	thus RB 0	leading VBG B-verb.stative	to TO 0	inter VB B-verb.communication	- : 0	patient JJ B-adj.all	variation NN B-noun.communication	in IN 0	ultimate JJ B-adj.all	prothrombin NN B-noun.person	effect NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d531.s10	Antihistamines NNS 0	, , 0	Benzodiazepines NNP B-noun.group	GI NNP I-noun.group	Motility NNP I-noun.group	Agents NNPS I-noun.group	Anti NNP I-noun.group	- : 0	Migraine NNP B-noun.person	Antifungal NNP I-noun.person	. . 0
DDI-DrugBank.d340.s23	This DT 0	change NN B-noun.act	was VBD B-verb.stative	not RB B-adv.all	considered VBN B-verb.cognition	clinically RB B-adv.all	significant JJ B-adj.all	and CC 0	no DT 0	dose NN B-noun.relation	adjustment NN I-noun.relation	is VBZ 0	needed VBN B-verb.consumption	when WRB 0	ketoconazole NN B-noun.person	and CC 0	VIRACEPT NNP 0	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d112.s1	The DT 0	effect NN B-noun.cognition	of IN 0	dofetilide NN 0	on IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	was VBD 0	evaluated VBN B-verb.change	in IN 0	a DT 0	randomized VBN B-verb.cognition	, , 0	double RB 0	- : 0	blind JJ B-adj.all	study NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d66.s1	The DT 0	present JJ B-adj.all	work NN B-noun.cognition	involved VBD B-verb.stative	the DT 0	administration NN B-noun.time	of IN 0	both DT 0	ethynyl_estradiol NNP B-noun.person	and CC 0	levonorgestrel NN B-noun.attribute	to TO 0	groups NNS B-noun.group	of IN 0	rats NNS B-noun.animal	, , 0	followed VBN B-verb.stative	by IN 0	determination NN B-noun.cognition	of IN 0	the DT 0	homocysteine NN B-noun.location	excretion NN 0	rate NN B-noun.time	in IN 0	urine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d420.s11	The DT 0	reddish JJ B-adj.all	color NN B-noun.group	is VBZ B-verb.stative	due JJ 0	to TO 0	the DT 0	formation NN B-noun.act	of IN 0	a DT 0	nonabsorbable JJ B-adj.all	complex NN B-noun.person	between IN 0	cefdinir NN B-noun.location	or CC 0	its PRP$ 0	breakdown NN B-noun.location	products NNS B-noun.person	and CC 0	iron NN B-noun.person	in IN 0	the DT 0	gastrointestinal JJ B-adj.all	tract NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d469.s10	TRACRIUM NN B-noun.artifact	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	until IN 0	a DT 0	patient NN B-noun.person	has VBZ 0	recovered VBN B-verb.body	from IN 0	succinylcholine NN B-noun.person	- : 0	induced VBN B-verb.creation	neuromuscular JJ B-adj.all	block NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d175.s18	Lithium NNP B-noun.person	, , 0	Increased VBD B-verb.change	serum NN B-noun.body	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	symptoms NNS B-noun.communication	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	lithium NN B-noun.substance	and CC 0	ACE_inhibitor NNP B-noun.person	therapy NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s11	When WRB 0	warfarin NN 0	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	nevirapine NN B-noun.person	, , 0	anticoagulation NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	frequently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d450.s8	There EX 0	have VBP 0	been VBN B-verb.stative	inconsistent JJ B-adj.all	reports NNS B-noun.communication	regarding VBG B-verb.stative	the DT 0	effects NNS B-noun.phenomenon	of IN 0	other JJ 0	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	quinine NN B-noun.location	, , 0	penicillamine NN 0	) ) 0	on IN 0	serum NN 0	digoxin NN 0	concentration NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d546.s3	There EX 0	is VBZ B-verb.stative	limited JJ B-adj.all	experience NN B-noun.person	with IN 0	concomitant JJ B-adj.all	antihypertensive_agents NNS B-noun.event	such JJ 0	as IN 0	alpha NN B-noun.person	- : 0	blockers NNS B-noun.person	, , 0	calcium_channel NNS B-noun.person	- : 0	blockers NNS B-noun.person	, , 0	ACE_inhibitors NNS B-noun.person	, , 0	and CC 0	diuretics NNS B-noun.person	( ( 0	both DT 0	thiazide JJ 0	- : 0	like IN 0	and CC 0	loop VB B-verb.perception	) ) 0	. . 0	. . 0
DDI-DrugBank.d494.s0	Concomitant JJ B-adj.all	use NN 0	with IN 0	other JJ B-adj.all	calcium NN B-noun.person	- : 0	containing VBG B-verb.stative	medicines NNS B-noun.substance	( ( 0	including VBG B-verb.body	antacids NNS I-verb.body	) ) 0	may MD 0	cause VB B-verb.cognition	too RB 0	much JJ B-adj.all	calcium NN B-noun.communication	in IN 0	the DT 0	blood NN B-noun.act	or CC 0	urine NN B-noun.location	, , 0	which WDT 0	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d106.s8	Chloral_hydrate NN B-noun.artifact	and CC 0	methaqualone NN 0	interact NN 0	pharmacologically RB B-adv.all	with IN 0	orally RB B-adj.all	administered VBN I-adj.all	anticoagulant_agents NNS B-noun.person	, , 0	but CC 0	the DT 0	effect NN B-noun.cognition	is VBZ B-verb.stative	not RB B-adv.all	clinically RB B-adv.all	significant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d476.s4	Concurrent JJ B-adj.all	use NN 0	of IN 0	rifampin NN B-noun.communication	increases VBZ B-verb.change	the DT 0	metabolic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	ZEBETA NNP B-noun.other	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	shortened VBN B-verb.communication	elimination NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	ZEBETA NNP B-noun.other	. . 0	. . 0
DDI-DrugBank.d6.s2	If IN 0	the DT 0	usual JJ B-adj.all	amounts NNS B-noun.quantity	of IN 0	nondepolarizing VBG B-verb.communication	relaxants NNS B-noun.person	are VBP 0	given VBN B-verb.possession	, , 0	the DT 0	time NN B-noun.time	for IN 0	recovery NN B-noun.act	from IN 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	will MD 0	be VB B-verb.stative	longer RBR B-adv.all	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	Enflurane NNP B-noun.person	than IN 0	when WRB 0	halothane NN B-noun.person	or CC 0	nitrous_oxide JJ 0	with IN 0	a DT 0	balanced JJ B-adj.all	technique NN B-noun.artifact	are VBP 0	used VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d516.s5	Magnesium- NN B-noun.person	and CC 0	aluminum NN B-noun.person	- : 0	containing VBG B-verb.stative	antacids NNS B-noun.substance	, , 0	administered VBN B-verb.body	concomitantly RB B-adv.all	with IN 0	lomefloxacin NN B-noun.food	, , 0	significantly RB B-adv.all	decreased VBD B-verb.change	the DT 0	bioavailability NN B-noun.cognition	( ( 0	48 CD 0	% NN 0	) ) 0	of IN 0	lomefloxacin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d532.s4	Patients NNS B-noun.person	with IN 0	HACA NNP B-noun.group	titers NNS B-noun.animal	may MD 0	have VB B-verb.change	allergic JJ B-adj.all	or CC 0	hypersensitivity NN B-noun.act	reactions NNS I-noun.act	when WRB 0	treated VBN B-verb.communication	with IN 0	other JJ 0	diagnostic JJ B-adj.all	or CC 0	therapeutic_monoclonal_antibodies NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d411.s18	Theophylline PRP 0	, , 0	Theophylline JJ 0	clearance NN B-noun.act	may MD 0	decrease VB B-verb.cognition	in IN 0	hypothyroid JJ B-adj.all	patients NNS B-noun.person	and CC 0	return VB B-verb.motion	toward IN 0	normal JJ B-adj.all	when WRB 0	a DT 0	euthyroid JJ B-adj.all	state NN B-noun.state	is VBZ 0	achieved VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d425.s1	Medications NNS B-noun.person	can MD 0	interfere VB B-verb.stative	with IN 0	folate JJ B-adj.all	utilization NN B-noun.act	, , 0	including VBG B-verb.change	, , 0	anticonvulsant_medications NNS B-noun.attribute	( ( 0	such JJ 0	as IN 0	phenytoin NN B-noun.person	, , 0	and CC 0	primidone NN 0	) ) 0	metformin NN B-noun.substance	( ( 0	sometimes RB B-adv.all	prescribed VBN B-verb.communication	to TO 0	control VB B-verb.social	blood NN B-noun.act	sugar NN B-noun.state	in IN 0	type NN B-noun.communication	2 CD B-adj.all	diabetes NNS B-noun.event	) ) 0	sulfasalazine NN 0	( ( 0	used VBN B-verb.consumption	to TO 0	control VB B-verb.social	inflammation NN B-noun.act	associated VBN B-verb.cognition	with IN 0	Crohns NNP B-noun.person	disease NN I-noun.person	and CC 0	ulcerative JJ B-adj.all	colitis NN B-noun.attribute	) ) 0	triamterene NN B-verb.social	( ( 0	a DT 0	diuretic JJ B-adj.all	) ) 0	Methotrexate NNP B-noun.location	There EX 0	has VBZ 0	been VBN 0	concern NN B-noun.feeling	about IN 0	the DT 0	interaction NN B-noun.act	between IN 0	vitamin_B12 NNP B-noun.person	and CC 0	folic_acid JJ 0	. . 0	. . 0
DDI-DrugBank.d231.s13	Tablets NNS B-noun.artifact	, , 0	Injection NNP B-noun.person	, , 0	and CC 0	Oral NNP B-noun.location	Solution NNP I-noun.location	One CD 0	study NN B-verb.cognition	in IN 0	six CD 0	subjects NNS B-noun.person	demonstrated VBD B-verb.cognition	that IN 0	the DT 0	combination NN B-noun.event	of IN 0	furosemide NN B-noun.artifact	and CC 0	acetylsalicylic_acid NNP B-noun.person	temporarily RB B-adv.all	reduced VBN B-verb.change	creatinine NN 0	clearance NN B-noun.attribute	in IN 0	patients NNS B-noun.person	with IN 0	chronic JJ B-adj.all	renal JJ B-adj.all	insufficiency NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d241.s1	When WRB 0	other JJ B-adj.all	antiplatelet_agents NNS B-noun.plant	or CC 0	anticoagulants NNS B-noun.animal	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	there EX 0	is VBZ B-verb.stative	the DT 0	potential NN B-noun.person	for IN 0	FLOLAN NNP B-noun.group	to TO 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d337.s3	Experience NN B-noun.person	with IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	and CC 0	Fentanyl NNP B-noun.person	in IN 0	patients NNS B-noun.person	is VBZ 0	limited VBN B-verb.change	, , 0	therefore RB B-adv.all	, , 0	consideration NN B-noun.group	should MD 0	be VB 0	given VBN B-verb.possession	to TO 0	temporarily RB 0	suspending VBG B-verb.social	use NN B-noun.process	of IN 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	Fentanyl NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d204.s1	Antidiabetic_drugs NNS B-noun.animal	( ( 0	oral JJ B-adj.all	agents NNS B-noun.person	and CC 0	insulin NN B-noun.body	) ) 0	, , 0	hypoglycemia NN B-noun.person	or CC 0	hyperglycemia NN B-noun.location	, , 0	. . 0
DDI-DrugBank.d568.s1	Alcohol NNP B-noun.person	; : 0	Although IN 0	LEXAPRO NNP B-noun.group	did VBD 0	not RB B-adv.all	potentiate VB B-verb.communication	the DT 0	cognitive NN B-noun.artifact	and CC 0	motor NN B-noun.person	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.food	in IN 0	a DT 0	clinical JJ B-adj.all	trial NN B-noun.cognition	, , 0	as IN 0	with IN 0	other JJ B-adj.all	psychotropic_medications NNS B-noun.person	, , 0	the DT 0	use NN 0	of IN 0	alcohol NN B-noun.food	by IN 0	patients NNS B-noun.person	taking VBG B-verb.social	LEXAPRO NNP B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d76.s13	The DT 0	clearance NN B-noun.attribute	of IN 0	benzodiazepines NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	glucuronidation NN B-noun.person	( ( 0	e. FW 0	g. FW 0	, , 0	lorazepam NN B-noun.person	, , 0	oxazepam NN B-noun.person	, , 0	temazepam NN B-noun.artifact	) ) 0	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	be VB 0	affected VBN B-verb.change	by IN 0	fluvoxamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s19	Methotrexate NNP B-noun.person	VIOXX NNP I-noun.person	12.5 CD 0	, , 0	25 CD B-adj.all	, , 0	and CC 0	50 CD B-adj.all	mg NN B-noun.quantity	, , 0	each DT 0	dose NN 0	administered VBN 0	once RB B-adv.all	daily RB B-adv.all	for IN 0	7 CD B-adj.all	days NNS B-noun.act	, , 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	methotrexate NN B-noun.attribute	as IN 0	measured VBN B-verb.cognition	by IN 0	AUC0 SYM 0	- : 0	24hr JJ 0	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	single JJ B-adj.all	weekly JJ B-adj.all	methotrexate NN B-noun.attribute	doses NNS B-noun.quantity	of IN 0	7.5 CD 0	to TO 0	20 CD B-adj.all	mg NN B-noun.quantity	for IN 0	rheumatoid JJ B-adj.all	arthritis NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d313.s13	When WRB 0	used VBN B-verb.consumption	in IN 0	external JJ B-adj.all	subcutaneous JJ B-adj.all	infusion NN B-noun.phenomenon	pumps NNS B-noun.artifact	for IN 0	insulin NN B-noun.person	, , 0	NovoLog NNP B-noun.person	should MD 0	not RB 0	be VB 0	mixed VBN B-verb.change	with IN 0	any DT 0	other JJ 0	insulins NNS B-noun.possession	or CC 0	diluent NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d195.s3	Although IN 0	there EX 0	have VBP 0	been VBN B-verb.stative	no RB 0	formal JJ 0	interaction NN B-noun.act	studies NNS B-noun.artifact	other JJ 0	than IN 0	with IN 0	antipyrine NN B-noun.attribute	, , 0	based VBN B-verb.cognition	on IN 0	these DT 0	in IN 0	vivo NN B-noun.animal	and CC 0	in IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	, , 0	it PRP 0	is VBZ B-verb.stative	unlikely JJ B-adj.all	that IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	a DT 0	1 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	ARIMIDEX NNP B-noun.group	with IN 0	other JJ 0	drugs NNS B-noun.artifact	will MD 0	result VB B-verb.stative	in IN 0	clinically RB B-adv.all	significant JJ B-adj.all	drug NN 0	inhibition NN 0	of IN 0	cytochrome NN B-noun.person	P450-mediated VBD B-verb.possession	metabolism NN B-noun.attribute	of IN 0	the DT 0	other JJ B-adj.all	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d172.s22	Warfarin NNP B-noun.person	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	celecoxib NN B-noun.body	on IN 0	the DT 0	anti NNS B-noun.person	- : 0	coagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.location	was VBD 0	studied VBN B-verb.cognition	in IN 0	a DT 0	group NN 0	of IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	receiving VBG B-verb.communication	daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	2 CD B-adj.all	- : 0	5 CD B-adj.all	mg NN B-noun.quantity	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d143.s45	Some DT 0	drugs NNS B-noun.artifact	/ POS 0	substances NNS B-noun.artifact	are VBP 0	known VBN B-verb.cognition	to TO 0	accelerate VB B-verb.communication	the DT 0	metabolism NN B-noun.attribute	of IN 0	amiodarone NN 0	by IN 0	stimulating VBG B-verb.change	the DT 0	synthesis NN B-noun.cognition	of IN 0	CYP3A4 NNP B-noun.person	( ( 0	enzyme JJ B-adj.all	induction NN B-noun.event	) ) 0	. . 0	. . 0
DDI-DrugBank.d137.s7	Oral NNP B-noun.person	Hypoglycemics NNP I-noun.person	, , 0	Bepridil NNP B-noun.person	has VBZ 0	been VBN 0	safely RB B-adv.all	used VBN B-verb.consumption	in IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	without IN 0	significantly RB B-adv.all	lowering VBG B-verb.motion	their PRP$ 0	blood NN B-noun.location	glucose NN B-noun.state	levels NNS B-noun.state	or CC 0	altering VBG B-verb.change	their PRP$ 0	need NN B-noun.motive	for IN 0	insulin NN B-noun.possession	or CC 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d219.s23	Short JJ B-noun.body	- : 0	term NN B-noun.time	pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	have VBP 0	demonstrated VBN B-verb.cognition	that IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	warfarin NN B-noun.act	and CC 0	Lodine NNP B-noun.person	_ : 0	( ( 0	etodolac NN B-noun.animal	capsules NNS I-noun.animal	and CC 0	tablets NNS B-noun.artifact	) ) 0	results NNS B-noun.communication	in IN 0	reduced JJ B-adj.all	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	warfarin NN B-noun.location	, , 0	but CC 0	there EX 0	was VBD B-verb.stative	no DT 0	change NN B-noun.act	in IN 0	the DT 0	clearance NN B-noun.act	of IN 0	free JJ B-adj.all	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d82.s32	Most JJS 0	of IN 0	the DT 0	above JJ 0	effects NNS B-noun.phenomenon	concerning VBG B-verb.communication	diuretics NNS B-noun.person	have VBP 0	been VBN 0	attributed VBN B-verb.contact	, , 0	at IN 0	least JJS 0	in IN 0	part NN 0	, , 0	to TO 0	mechanisms NNS B-noun.person	involving VBG B-verb.communication	inhibition NN B-noun.attribute	of IN 0	prostaglandin NN B-noun.substance	synthesis NN B-noun.food	by IN 0	INDOCIN NNP 0	. . 0	. . 0
DDI-DrugBank.d382.s17	In IN 0	patients NNS B-noun.person	on IN 0	chronic JJ B-adj.all	warfarin NN B-noun.act	therapy NN B-noun.act	, , 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	( ( 0	INR NNP 0	) ) 0	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	in IN 0	the DT 0	2-week JJ B-adj.all	period NN B-noun.person	, , 0	particularly RB B-adv.all	at IN 0	7 CD 0	to TO 0	10 CD B-adj.all	days NNS B-noun.time	, , 0	following VBG 0	initiation NN B-noun.act	of IN 0	the DT 0	3-day JJ B-adj.all	regimen NNS B-noun.person	of IN 0	Aprepitant NNP B-noun.person	with IN 0	each DT 0	chemotherapy NN B-noun.communication	cycle NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d565.s22	The DT 0	depression NN B-noun.act	of IN 0	cardiac JJ B-noun.substance	contractility NN I-noun.substance	, , 0	conductivity NN B-noun.person	, , 0	and CC 0	automaticity NN B-noun.person	as RB 0	well RB 0	as IN 0	the DT 0	vascular JJ B-adj.all	dilation NN B-noun.act	associated VBN B-verb.cognition	with IN 0	anesthetics NNS B-noun.person	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	calcium_channel_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s23	Therefore RB 0	, , 0	such JJ 0	combined VBN B-verb.change	treatment NN B-noun.group	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	and CC 0	patients NNS B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	when WRB 0	Clozapine NNP B-noun.person	is VBZ 0	combined VBN B-verb.change	with IN 0	these DT 0	drugs NNS B-noun.artifact	, , 0	particularly RB B-adv.all	with IN 0	fluvoxamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d450.s3	Erythromycin NNP B-noun.person	and CC 0	clarithromycin NN B-noun.person	( ( 0	and CC 0	possibly RB B-adj.all	other JJ I-adj.all	macrolide_antibiotics NNS B-noun.person	) ) 0	and CC 0	tetracycline NN B-noun.act	may MD 0	increase VB B-verb.emotion	digoxin NN I-verb.emotion	absorption NN B-noun.process	in IN 0	patients NNS B-noun.person	who WP 0	inactivate VBP B-verb.communication	digoxin NN B-noun.person	by IN 0	bacterial JJ B-adj.all	metabolism NN B-noun.attribute	in IN 0	the DT 0	lower JJR B-adj.all	intestine NN B-noun.person	, , 0	so RB B-adv.all	that IN 0	digitalis PRP$ 0	intoxication NN B-noun.act	may MD 0	result VB B-verb.stative	. . 0	. . 0
DDI-MedLine.d87.s2	Gastrointestinal JJ B-adj.all	transit NN B-noun.event	time NN B-noun.time	( ( 0	lactulose JJ B-adj.all	hydrogen NN 0	breath NN 0	test NN 0	) ) 0	was VBD 0	measured VBN B-verb.cognition	in IN 0	14 CD B-adj.all	volunteers NNS B-noun.person	with IN 0	oral JJ B-adj.all	and CC 0	intravenous JJ B-adj.all	placebo NN B-noun.communication	, , 0	oral JJ B-adj.all	placebo NN B-noun.plant	and CC 0	intravenous JJ B-adj.all	morphine NN B-noun.person	( ( 0	0.05 CD 0	mg NN B-noun.quantity	x IN 0	kg(-1 NNP 0	) ) 0	) ) 0	, , 0	and CC 0	oral JJ B-adj.all	ADL_8 NNS B-noun.person	- : 0	2698 CD 0	( ( 0	4 CD B-adj.all	mg NN B-noun.quantity	) ) 0	and CC 0	intravenous JJ B-adj.all	morphine NN B-noun.person	( ( 0	0.05 CD 0	mg NN B-noun.quantity	x IN 0	kg(-1 NNP 0	) ) 0	) ) 0	in IN 0	a DT 0	double JJ B-adj.all	blind NN B-noun.person	, , 0	cross VBP B-verb.motion	- : 0	over IN 0	study NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d132.s27	Naproxen NNP B-noun.person	, , 0	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.state	and CC 0	naproxen NN B-noun.person	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	naproxen NN B-noun.person	, , 0	but CC 0	significantly RB B-adv.all	decreased VBD B-verb.change	the DT 0	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	naproxen NN B-noun.person	and CC 0	its PRP$ 0	glucuronide NN 0	metabolite NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d314.s4	Anticholinesterases NNS B-noun.person	, , 0	Concomitant JJ 0	use NN 0	of IN 0	anticholinesterase_agents NNS B-noun.location	and CC 0	corticosteroids NNS B-noun.object	may MD 0	produce VB B-verb.cognition	severe JJ B-adj.all	weakness NN B-noun.state	in IN 0	patients NNS B-noun.person	with IN 0	myasthenia NN B-noun.person	gravis NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d3.s13	Methotrexate NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	methotrexate NN B-noun.food	and CC 0	some DT 0	NSAIDs NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	methotrexate NN B-noun.food	, , 0	enhancing VBG B-verb.change	the DT 0	toxicity NN B-noun.attribute	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d113.s6	Propoxyphene NNP B-noun.person	, , 0	The DT 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	propoxyphene_hydrochloride NN 0	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	meclofenamate_sodium NN B-noun.person	. . 0	. . 0
DDI-MedLine.d105.s5	Antiretroviral JJ B-adj.all	plasma NN B-noun.attribute	and CC 0	urine NN 0	sampling VBG 0	were VBD 0	conducted VBN B-verb.consumption	on IN 0	Days NNS B-noun.time	1 CD 0	, , 0	7 CD 0	, , 0	and CC 0	21 CD B-adj.all	for IN 0	zidovudine NN B-noun.act	and CC 0	on IN 0	Days NNPS B-verb.creation	7 CD 0	and CC 0	21 CD B-adj.all	for IN 0	dideoxyinosine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d154.s7	Patients NNS B-noun.person	receiving VBG B-verb.communication	hydantoins NNS B-noun.person	, , 0	sulfonamides VBZ B-verb.motion	, , 0	or CC 0	sulfonylureas NNS B-noun.location	should MD 0	be VB 0	observed VBN B-verb.perception	for IN 0	increased JJ B-adj.all	activity NN B-noun.process	of IN 0	these DT 0	drugs NNS B-noun.artifact	and CC 0	, , 0	therefore RB B-adv.all	, , 0	signs NNS B-noun.communication	of IN 0	toxicity NN B-noun.attribute	from IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d328.s49	Although IN 0	the DT 0	magnitude NN B-noun.person	of IN 0	changes NNS B-noun.phenomenon	in IN 0	diazepam NN 0	plasma NN 0	exposure NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	valdecoxib NN B-noun.attribute	were VBD B-verb.stative	not RB B-adv.all	sufficient JJ B-adj.all	to TO 0	warrant JJ B-adj.all	dosage NN B-noun.artifact	adjustments NNS B-noun.person	, , 0	patients NNS B-noun.person	may MD 0	experience VB B-verb.communication	enhanced JJ B-verb.change	sedative JJ B-adj.all	side NN B-noun.artifact	effects NNS B-noun.phenomenon	caused VBN B-verb.communication	by IN 0	increased VBN B-verb.change	exposure NN B-noun.state	of IN 0	diazepam NN B-noun.person	under IN 0	this DT 0	circumstance NN B-noun.act	. . 0	. . 0
DDI-MedLine.d51.s3	The DT 0	anxiogenic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	theophylline PRP 0	were VBD 0	reduced VBN B-verb.change	by IN 0	pretreatment NN B-noun.person	with IN 0	CGS_21680 NNP B-noun.person	, , 0	an DT 0	A2-selective JJ B-adj.all	agonist NN B-noun.person	, , 0	but CC 0	not RB B-adv.all	by IN 0	N6-cyclopentyladenosine JJ 0	( ( 0	CPA NNP 0	) ) 0	, , 0	an DT 0	A1-selective JJ B-adj.all	agonist NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d196.s43	PEGASYS NNP B-noun.group	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	with IN 0	creatinine JJ B-adj.all	clearance NN B-noun.attribute	_ $ 0	50 CD B-adj.all	mL CD B-noun.quantity	/ JJ B-adj.all	min NN B-noun.substance	and CC 0	COPEGUS NNP B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.perception	to TO 0	patients NNS B-noun.person	with IN 0	creatinine JJ B-adj.all	clearance NN B-noun.attribute	_ $ 0	50 CD B-adj.all	mL CD B-noun.quantity	/ JJ B-adj.all	min NN B-noun.substance	. . 0
DDI-DrugBank.d409.s0	Because IN 0	the DT 0	tetracyclines NNS B-noun.artifact	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	depress VB B-verb.motion	plasma NN 0	prothrombin NN 0	activity NN B-noun.state	, , 0	patients NNS B-noun.person	who WP 0	are VBP B-verb.stative	on IN 0	anticoagulant JJ B-adj.all	therapy NN B-noun.act	may MD 0	require VB B-verb.stative	downward JJ B-adj.all	adjustment NN B-noun.act	of IN 0	their PRP$ 0	anticoagulant JJ B-adj.all	dosage NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d471.s1	Administration NN B-noun.person	of IN 0	thiazide_diuretics NNS B-noun.person	to TO 0	hypoparathyroid VB B-verb.social	patients NNS B-noun.person	who WP 0	are VBP 0	concurrently RB 0	being VBG 0	treated VBN B-verb.change	with IN 0	ergocalciferol NN B-noun.act	may MD 0	cause VB B-verb.emotion	hypercalcemia NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d66.s0	Human_growth_hormone CD 0	; : 0	Concomitant JJ B-adj.all	use NN 0	of IN 0	L NNP 0	- : 0	glutamine NN B-noun.person	and CC 0	human_growth_hormone NNP B-noun.person	may MD 0	enhance VB B-verb.change	nutrient JJ B-adj.all	absorption NN B-noun.person	in IN 0	those DT 0	with IN 0	severe JJ B-verb.contact	short JJ B-adj.all	bowel NN B-noun.artifact	syndrome NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d137.s11	Cardiac_glycosides NNS B-noun.artifact	could MD 0	exaggerate VB B-verb.communication	the DT 0	depression NN B-noun.act	of IN 0	AV NNP 0	nodal JJ B-adj.all	conduction NN B-noun.feeling	observed VBN B-verb.perception	with IN 0	bepridil_hydrochloride NN 0	. . 0	. . 0
DDI-DrugBank.d299.s10	Coadministration NN B-noun.person	of IN 0	almotriptan JJ B-noun.animal	and CC 0	the DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	ketoconazole NN B-noun.person	( ( 0	400 CD 0	mg IN 0	q.d NNP 0	. . 0	for IN 0	3 CD B-adj.all	days NNS B-noun.artifact	) ) 0	resulted VBD B-verb.stative	in IN 0	an DT 0	approximately RB B-adv.all	60 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	area NN B-noun.body	under IN 0	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	- : 0	time NN B-noun.time	curve NN B-noun.communication	and CC 0	maximal JJ B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	almotriptan NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d334.s10	Other JJ 0	Agents NNPS B-noun.person	, , 0	PRINIVIL NNP B-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	nitrates NNS B-noun.person	and/or CC 0	digoxin NN B-noun.attribute	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d61.s9	These DT 0	alterations NNS B-noun.act	in IN 0	digoxin NN B-noun.person	pharmacokinetics NNS B-noun.person	produced VBN B-verb.creation	by IN 0	amiodarone NN 0	explain VB B-verb.communication	the DT 0	increase NN B-noun.event	in IN 0	serum NN B-noun.body	digoxin NN B-noun.attribute	level NN I-noun.attribute	that WDT 0	has VBZ 0	been VBN 0	observed VBN B-verb.perception	when WRB 0	this DT 0	drug NN 0	combination NN 0	has VBZ 0	been VBN 0	used VBN B-verb.consumption	clinically RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d438.s40	Effect NN 0	of IN 0	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	is VBZ B-verb.stative	a DT 0	blocker NN B-noun.person	of IN 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d382.s30	therefore RB B-adv.all	, , 0	coadministration NN B-noun.person	of IN 0	Aprepitant NNP B-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	CYP3A4 JJ B-adj.all	activity NN B-noun.process	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	aprepitant NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s24	Prednisone NNP 0	/ : 0	prednisolone NN B-noun.substance	, , 0	Rofecoxib NNP B-noun.person	did VBD 0	not RB B-adv.all	have VB B-verb.change	any DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	prednisolone NN B-noun.substance	or CC 0	prednisone NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d219.s6	however RB 0	, , 0	as IN 0	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Lodine NNP B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	generally RB B-adv.all	recommended VBN B-verb.communication	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	of IN 0	increased VBN B-verb.change	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d237.s1	In IN 0	some DT 0	cases NNS B-noun.artifact	where WRB 0	serious JJ B-adj.all	ventricular JJ B-adj.all	arrhythmias NN B-noun.communication	, , 0	QT NNP 0	prolongation NN 0	, , 0	and CC 0	torsades VBZ B-verb.motion	de IN 0	pointes NNS B-noun.time	have VBP 0	occurred VBN B-verb.cognition	when WRB 0	cisapride NN B-noun.person	was VBD 0	taken VBN B-verb.social	in IN 0	conjunction NN 0	with IN 0	one CD 0	of IN 0	the DT 0	cytochrome NN B-noun.person	P450 RB I-noun.person	3A4 JJ I-noun.person	inhibitors NNS I-noun.person	, , 0	elevated VBD B-verb.motion	blood NN B-noun.location	cisapride NN B-noun.location	levels NNS B-noun.state	were VBD 0	noted VBN B-verb.perception	at IN 0	the DT 0	time NN B-noun.time	of IN 0	the DT 0	QT NNP 0	prolongation NN 0	. . 0	. . 0
DDI-DrugBank.d40.s5	The DT 0	most RBS 0	significant JJ B-adj.all	drug NN B-noun.event	interactions NNS 0	following VBG 0	administration NN B-noun.person	of IN 0	Cerebyx NNP B-noun.person	are VBP 0	expected VBN B-verb.cognition	to TO 0	occur VB B-verb.stative	with IN 0	drugs NNS B-noun.artifact	that WDT 0	interact VBP B-verb.emotion	with IN 0	phenytoin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d42.s10	In IN 0	addition NN 0	, , 0	patients NNS B-noun.person	taking VBG B-verb.social	drugs NNS I-verb.social	that WDT 0	inhibit VBP B-verb.stative	the DT 0	cytochrome NN 0	P450 RB 0	3A4 JJ 0	isozyme NN B-noun.attribute	, , 0	which WDT 0	metabolizes VBZ B-verb.stative	sildenafil NN B-noun.attribute	, , 0	may MD 0	experience VB 0	increased VBN B-verb.change	drug NN B-noun.artifact	concentrations NNS B-noun.artifact	and CC 0	possible JJ B-adj.all	toxicity NN B-noun.attribute	from IN 0	normal JJ B-adj.all	doses NNS B-noun.event	of IN 0	sildenafil NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d83.s4	The DT 0	1-year JJ B-adj.all	risk NN B-noun.shape	of IN 0	relapse NN B-noun.act	( ( 0	rehospitalisation NN B-noun.act	) ) 0	was VBD B-verb.stative	significantly RB B-adv.all	lower RBR B-adj.all	with IN 0	olanzapine JJ 0	than IN 0	with IN 0	haloperidol NN B-noun.person	treatment NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d313.s5	In IN 0	addition NN 0	, , 0	under IN 0	the DT 0	influence NN B-noun.cognition	of IN 0	sympatholytic JJ B-adj.all	medicinal JJ B-adj.all	products NNS B-noun.cognition	such JJ 0	as IN 0	beta NNS B-noun.person	- : 0	blockers NNS B-noun.person	, , 0	clonidine NN B-noun.person	, , 0	guanethidine NN B-noun.person	, , 0	and CC 0	reserpine NN B-noun.act	, , 0	the DT 0	signs NNS B-noun.communication	of IN 0	hypoglycemia NN B-noun.animal	may MD 0	be VB 0	reduced VBN B-verb.change	or CC 0	absent JJ B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d458.s25	INH NNP 0	( ( 0	Isoniazid NNP B-noun.other	) ) 0	is VBZ B-verb.stative	also RB B-adv.all	reported VBD B-verb.communication	to TO 0	affect VB B-verb.change	ketoconazole JJ B-adj.all	concentrations NNS B-noun.person	adversely RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d163.s16	Systemic_Corticosteroids NNS B-noun.body	, , 0	Systemic_corticosteroids NNS B-noun.body	are VBP 0	known VBN B-verb.cognition	to TO 0	cause VB B-verb.communication	osteoporosis NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d60.s5	The DT 0	interaction NN B-noun.act	may MD 0	be VB B-verb.stative	a DT 0	result NN B-noun.act	of IN 0	inhibition NN B-noun.attribute	of IN 0	both DT 0	CYP2C9 NNP B-noun.person	and CC 0	2C19 JJ 0	by IN 0	fluvoxamine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d74.s4	Glucose NNP B-noun.person	, , 0	alone RB 0	and CC 0	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	theophylline NN 0	, , 0	caused VBD B-verb.communication	subnormal JJ B-adj.all	insulin NN B-noun.state	release NN I-noun.state	and CC 0	less JJR B-adj.all	suppression NN B-noun.act	of IN 0	glucagon NN B-noun.phenomenon	release NN B-noun.process	in IN 0	the DT 0	diabectics NNS B-noun.person	than IN 0	in IN 0	the DT 0	normals NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d375.s0	The DT 0	potential NN B-noun.person	for IN 0	drug NN B-noun.act	interactions NNS I-noun.act	with IN 0	EMTRIVA NNP B-noun.group	has VBZ 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	combination NN 0	with IN 0	indinavir NN B-noun.person	, , 0	stavudine NN B-noun.location	, , 0	famciclovir NN B-noun.person	, , 0	and CC 0	tenofovir_disoproxil_fumarate NNP B-noun.location	. . 0	. . 0
DDI-MedLine.d94.s13	Radioligand RB 0	binding JJ B-verb.contact	experiments NNS B-noun.person	using VBG B-verb.consumption	the DT 0	uptake NN B-noun.location	inhibitor VB B-verb.stative	hydrogen-3 JJ B-adj.all	mazindol NN B-noun.person	revealed VBD B-verb.perception	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	by IN 0	approximately RB B-noun.time	30 CD B-adj.all	% NN 0	in IN 0	norepinephrine JJ B-adj.all	uptake-1 JJ B-adj.all	carrier NN B-noun.artifact	density NN I-noun.artifact	in IN 0	functional JJ B-adj.all	classes NNS B-noun.group	II NNP 0	to TO 0	III NNP 0	and CC 0	IV NNP 0	myocardium NN 0	versus NN 0	nonfailing VBG B-verb.communication	myocardium NN B-noun.person	( ( 0	p IN 0	< $ 0	0.05 CD 0	) ) 0	. . 0	. . 0
DDI-MedLine.d125.s5	We PRP 0	demonstrate VBP B-verb.cognition	that IN 0	the DT 0	conversion NN B-noun.cognition	of IN 0	1,3-difluoro-2-propanol CD 0	to TO 0	1,3-difluoroacetone JJ 0	by IN 0	an DT 0	NAD+-dependent JJ B-adj.all	oxidation NN B-noun.communication	is VBZ B-verb.stative	the DT 0	rate NN B-noun.time	- : 0	limiting VBG B-verb.body	step NN I-verb.body	in IN 0	the DT 0	synthesis NN B-noun.cognition	of IN 0	the DT 0	toxic JJ B-adj.all	product NN B-noun.substance	, , 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate NN B-noun.person	from IN 0	1,3-difluoro-2-propanol NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d382.s41	Diltiazem NNP B-noun.person	, , 0	In IN 0	patients NNS B-noun.person	with IN 0	mild JJ 0	to TO 0	moderate JJ B-adj.all	hypertension NN B-noun.person	, , 0	administration NN B-noun.person	of IN 0	aprepitant JJ B-adj.all	once RB B-adv.all	daily RB I-adv.all	, , 0	as IN 0	a DT 0	tablet NN B-noun.phenomenon	formulation NN I-noun.phenomenon	comparable JJ B-adj.all	to TO 0	230 CD 0	mg NN B-noun.quantity	of IN 0	the DT 0	capsule NN B-noun.location	formulation NN B-noun.act	, , 0	with IN 0	diltiazem NN B-noun.communication	120 CD 0	mg NN B-noun.quantity	3 CD B-adj.all	times NNS B-noun.event	daily RB B-adv.all	for IN 0	5 CD B-adj.all	days NNS B-noun.person	, , 0	resulted VBD B-verb.stative	in IN 0	a DT 0	2-fold JJ B-adj.all	increase NN B-noun.event	of IN 0	aprepitant JJ B-adj.all	AUC NNP B-noun.group	and CC 0	a DT 0	simultaneous JJ B-adj.all	1.7-fold JJ B-adj.all	increase NN B-noun.event	of IN 0	diltiazem NN 0	AUC NNP 0	. . 0	. . 0
DDI-DrugBank.d505.s0	No DT 0	pharmacokinetic JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	studies NNS B-noun.artifact	were VBD 0	conducted VBN B-verb.creation	with IN 0	PERSANTINE NNP B-noun.group	_ : 0	( ( 0	dipyridamole JJ B-adj.all	USP NNP B-noun.group	) ) 0	Tablets NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d219.s9	Patients NNS B-noun.person	receiving VBG B-verb.communication	these DT 0	drugs NNS B-noun.person	who WP 0	are VBP 0	given VBN B-verb.possession	Lodine NNP B-noun.person	, , 0	or CC 0	any DT 0	other JJ 0	NSAID NNP B-noun.group	, , 0	and CC 0	particularly RB B-verb.change	those DT 0	patients NNS B-noun.person	with IN 0	altered JJ B-adj.all	renal JJ B-adj.all	function NN B-noun.act	, , 0	should MD 0	be VB 0	observed VBN B-verb.perception	for IN 0	the DT 0	development NN B-noun.process	of IN 0	the DT 0	specific JJ B-adj.all	toxicities NNS B-noun.attribute	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d19.s1	DISULFIRAM NN B-noun.group	SHOULD MD 0	BE VB 0	USED VBN B-verb.consumption	WITH IN 0	CAUTION NN B-noun.group	IN IN 0	THOSE DT 0	PATIENTS NNS B-noun.group	REVEIVING VBG B-verb.change	PHENYTOIN NN B-noun.group	AND CC 0	ITS PRP$ 0	CONGENERS NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d190.s3	Concomitant JJ B-adj.all	use NN 0	of IN 0	prophylactic JJ B-adj.all	low JJ B-adj.all	dose NN 0	heparin NN 0	did VBD 0	not RB B-adv.all	appear VB B-verb.change	to TO 0	affect VB B-verb.change	safety NN B-noun.artifact	, , 0	however RB 0	, , 0	its PRP$ 0	effects NNS B-noun.phenomenon	on IN 0	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	Xigris NNP B-noun.location	have VBP 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	in IN 0	an DT 0	adequate JJ B-adj.all	and CC 0	well RB 0	- : 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trial NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d263.s13	Drugs NNS B-noun.artifact	that WDT 0	have VBP 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	peripheral JJ B-adj.pert	neuropathy NN B-noun.state	include VBP B-verb.stative	antiretroviral_nucleoside_analogues NNS I-verb.stative	, , 0	chloramphenicol NN B-noun.person	, , 0	cisplatin NN B-noun.person	, , 0	dapsone NN 0	, , 0	disulfiram NN B-noun.person	, , 0	ethionamide NN 0	, , 0	glutethimide NN 0	, , 0	gold NN B-noun.person	, , 0	hydralazine NN B-noun.person	, , 0	iodoquinol NN B-noun.person	, , 0	isoniazid NN B-noun.person	, , 0	metronidazole NN B-noun.attribute	, , 0	nitrofurantoin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	ribavirin NN 0	, , 0	and CC 0	vincristine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d297.s4	Concurrent JJ B-adj.all	therapy NN 0	with IN 0	ORENCIA NNP B-noun.group	and CC 0	TNF_antagonists NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d112.s0	Concurrent JJ B-adj.all	use NN 0	with IN 0	probenecid NN B-noun.person	or CC 0	other JJ B-adj.all	drugs NNS B-noun.person	significantly RB B-adv.all	eliminated VBN B-verb.cognition	by IN 0	active JJ B-adj.all	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	penciclovir NN B-noun.person	. . 0	. . 0
DDI-MedLine.d126.s1	Considering VBG B-verb.communication	that IN 0	the DT 0	involvement NN B-noun.person	of IN 0	reactive JJ B-adj.all	oxygen NN B-noun.animal	species NNS I-noun.animal	( ( 0	ROS NNP 0	) ) 0	has VBZ 0	been VBN 0	implicated VBN B-verb.communication	in IN 0	the DT 0	toxicity NN B-noun.attribute	of IN 0	various JJ B-adj.all	pesticides NNS B-noun.location	, , 0	this DT 0	study NN B-noun.artifact	was VBD 0	designed VBN B-verb.creation	to TO 0	investigate VB B-verb.communication	the DT 0	possibility NN B-noun.state	of IN 0	oxidative JJ B-adj.all	stress NN B-noun.state	induction NN 0	by IN 0	cypermethrin NN B-noun.person	, , 0	a DT 0	Type_II_pyrethroid JJ B-noun.person	. . 0	. . 0
DDI-DrugBank.d283.s5	Cyclosporine NNP B-noun.person	, , 0	Because IN 0	cyclosporine NN B-noun.person	can MD 0	produce VB B-verb.creation	nephrotoxicity NN I-verb.creation	with IN 0	decreases NNS B-noun.food	in IN 0	creatinine NN 0	clearance NN B-noun.attribute	and CC 0	rises VBZ B-verb.change	in IN 0	serum NN 0	creatinine NN 0	, , 0	and CC 0	because IN 0	renal JJ B-adj.all	excretion NN B-noun.act	is VBZ B-verb.stative	the DT 0	primary JJ B-adj.all	elimination NN B-noun.act	route NN B-noun.attribute	of IN 0	fibrate_drugs NNS B-noun.substance	including VBG B-verb.change	TRICOR NNP B-noun.group	, , 0	there EX 0	is VBZ B-verb.stative	a DT 0	risk NN 0	that IN 0	an DT 0	interaction NN B-noun.act	will MD 0	lead VB B-verb.stative	to TO 0	deterioration NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d384.s5	Some DT 0	reports NNS B-noun.artifact	have VBP 0	shown VBN B-verb.cognition	that IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	thiazides NNS 0	with IN 0	vitamin_D NNP B-noun.person	causes VBZ B-verb.creation	hypercalcemia NN I-verb.creation	. . 0	. . 0
DDI-DrugBank.d404.s10	However RB 0	, , 0	in IN 0	vivo JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.act	of IN 0	ketoconazole NN B-noun.shape	with IN 0	vitamin_D NNS B-noun.plant	have VBP 0	not RB 0	been VBN 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d476.s0	ZEBETA NNP B-noun.group	should MD 0	not RB 0	be VB 0	combined VBN B-verb.change	with IN 0	other JJ 0	beta JJ 0	- : 0	blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d90.s7	Recovery NN B-noun.process	of IN 0	hoof JJ B-noun.person	twitch NN I-noun.person	from IN 0	50 CD B-adj.all	% NN 0	to TO 0	75 CD 0	% NN 0	took VBD B-verb.contact	7.7 CD I-verb.contact	+ : 0	/- $ 0	0.7 CD 0	min NN B-noun.quantity	for IN 0	atracurium NN 0	alone RB 0	and CC 0	11.5 CD 0	+ : 0	/- $ 0	2.7 CD 0	min NN B-noun.quantity	for IN 0	atracurium NN B-noun.person	plus CC 0	gentamycin NN B-noun.communication	( ( 0	P RB 0	= JJ 0	0.03 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d54.s0	Oral NNP B-noun.group	Anticoagulants NNPS I-noun.group	, , 0	Thyroid_hormones NNS B-noun.body	appear VBP B-verb.change	to TO 0	increase VB B-verb.change	catabolism NN B-noun.artifact	of IN 0	vitamin NN B-noun.group	K SYM 0	- : 0	dependent JJ B-adj.all	clotting NN B-verb.contact	factors NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d78.s3	Advantages NNS B-noun.person	offered VBN B-verb.social	by IN 0	this DT 0	class NN B-noun.attribute	of IN 0	antibiotics NNS B-noun.person	include VBP B-verb.change	optimal JJ B-adj.all	pharmacokinetics NNS B-noun.person	, , 0	effectiveness NN B-noun.cognition	against IN 0	multidrug JJ B-noun.person	- : 0	resistant JJ B-adj.all	organisms NNS B-noun.cognition	, , 0	and CC 0	oral JJ B-adj.all	administration NN B-noun.time	even RB B-adv.all	when WRB 0	parenteral JJ B-adj.all	antibiotics NNS B-noun.person	are VBP 0	generally RB B-adv.all	used VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d148.s0	Heparin NNP B-noun.person	, , 0	Since IN 0	heparin NN 0	is VBZ 0	contraindicated VBN B-verb.communication	in IN 0	patients NNS B-noun.person	with IN 0	heparin NN B-noun.person	- : 0	induced VBN B-verb.creation	thrombocytopenia NN B-noun.artifact	, , 0	the DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Argatroban NNP B-noun.person	and CC 0	heparin NN B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	for IN 0	this DT 0	indication NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d329.s1	Based VBN B-verb.cognition	on IN 0	total JJ B-adj.all	ertapenem NN B-noun.body	concentrations NNS I-noun.body	, , 0	probenecid NN B-noun.person	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	by IN 0	25 CD B-adj.all	% NN 0	and CC 0	reduced VBD B-verb.change	the DT 0	plasma NN B-noun.plant	and CC 0	renal JJ B-noun.body	clearances NNS I-noun.body	by IN 0	20 CD B-adj.all	% NN 0	and CC 0	35 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d32.s6	A DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	liquid JJ B-adj.all	antacid NN B-noun.attribute	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	C NNP 0	max NN 0	or CC 0	AUC NNP B-noun.group	of IN 0	ceftibuten NN B-noun.food	, , 0	. . 0
DDI-MedLine.d23.s2	Ventricular JJ B-adj.all	tachycardia NN B-noun.shape	induced VBN B-verb.creation	by IN 0	ouabain NN B-noun.person	was VBD 0	generally RB B-adv.all	converted VBN B-verb.change	to TO 0	sinus VB 0	rhythm NN B-noun.act	following VBG B-verb.stative	administration NN B-noun.act	of IN 0	Innovar NNP B-noun.location	, , 0	ketamine NN B-noun.person	, , 0	or CC 0	droperidol NN B-noun.person	but CC 0	not RB B-adv.all	after IN 0	administration NN B-noun.time	of IN 0	fentayl NN B-noun.phenomenon	alone RB B-adv.all	or CC 0	after IN 0	pentobarbital JJ B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d398.s0	The DT 0	use NN 0	of IN 0	codeine NN B-noun.person	may MD 0	result VB B-verb.stative	in IN 0	additive JJ B-adj.all	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	when WRB 0	coadministered VBN B-verb.communication	with IN 0	alcohol NN B-noun.food	, , 0	antihistamines NNS B-noun.attribute	, , 0	psychotropics NNS B-noun.person	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	produce VBP B-verb.stative	CNS NNP 0	depression NN 0	. . 0	. . 0
DDI-DrugBank.d355.s3	In IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	, , 0	the DT 0	metabolic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	androgens NNS B-noun.animal	may MD 0	decrease VB B-verb.cognition	blood NN B-noun.act	glucose NN I-noun.act	and CC 0	therefore RB B-adv.all	, , 0	insulin NN B-noun.substance	requirements NNS B-noun.object	. . 0	. . 0
DDI-MedLine.d105.s4	Subjects NNS B-noun.person	treated VBN B-verb.social	with IN 0	200 CD 0	mg NN B-noun.quantity	of IN 0	dideoxyinosine NN B-noun.phenomenon	twice RB B-adv.all	daily RB B-adv.all	for IN 0	21 CD B-adj.all	days NNS B-noun.person	received VBD B-verb.possession	1200 CD 0	mg NN B-noun.quantity	of IN 0	azithromycin NN B-noun.substance	or CC 0	an DT 0	equivalent JJ B-adj.all	amount NN B-noun.possession	of IN 0	placebo NN 0	/ : 0	day NN B-noun.person	for IN 0	Days NNS B-noun.time	8 CD 0	to TO 0	21 CD 0	. . 0	. . 0
DDI-DrugBank.d491.s16	Since IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	AMEVIVE NNP B-noun.other	on IN 0	pregnancy NN B-noun.person	and CC 0	fetal JJ B-adj.all	development NN B-noun.process	, , 0	including VBG B-verb.change	immune JJ B-adj.all	system NN B-noun.body	development NN B-noun.process	, , 0	is VBZ B-verb.stative	not RB B-adj.all	known VBN I-adj.all	, , 0	health NN B-noun.person	care NN I-noun.person	providers NNS B-noun.person	are VBP 0	encouraged VBN B-verb.social	to TO 0	enroll VB B-verb.social	patients NNS B-noun.person	currently RB B-adv.all	taking VBG 0	AMEVIVE NNP B-noun.other	who WP 0	become VBP B-verb.stative	pregnant JJ B-adj.all	into IN 0	the DT 0	Biogen NNP B-noun.group	Pregnancy NNP I-noun.group	Registry NNP I-noun.group	by IN 0	calling VBG B-verb.communication	1 CD B-adj.all	- : 0	866-AMEVIVE JJ 0	( ( 0	1 CD 0	- : 0	866 CD 0	- : 0	263 CD 0	- : 0	8483 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d166.s1	Trecator NNP B-noun.person	may MD 0	potentiate VB B-verb.communication	the DT 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	other JJ B-adj.all	antituberculous_drugs NNS B-noun.object	administered VBN B-verb.perception	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d238.s6	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	several JJ B-adj.all	closely RB B-adj.all	related JJ I-adj.all	tricyclic_antidepressants NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	be VB 0	increased VBN B-verb.change	by IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	methylphenidate NN B-noun.attribute	or CC 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	cimetidine NN B-noun.person	, , 0	fluoxetine NN 0	) ) 0	and CC 0	decreased VBN B-verb.change	by IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	inducers NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	barbiturates NNS B-noun.person	, , 0	phenytoin NN B-noun.body	) ) 0	, , 0	and CC 0	such PDT 0	an DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	anticipated VBN B-verb.cognition	with IN 0	CMI NNP 0	as RB 0	well RB 0	. . 0	. . 0
DDI-DrugBank.d354.s1	Therefore RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	administering VBG B-verb.communication	nitazoxanide RB I-verb.communication	concurrently RB B-adv.all	with IN 0	other JJ 0	highly RB B-adv.all	plasma JJ B-adj.all	protein NN B-noun.person	- : 0	bound NN B-noun.person	drugs NNS B-noun.person	with IN 0	narrow JJ B-adj.all	therapeutic JJ B-adj.all	indices NNS B-noun.act	, , 0	as IN 0	competition NN B-noun.act	for IN 0	binding VBG B-verb.social	sites NNS B-noun.location	may MD 0	occur VB B-verb.stative	( ( 0	e.g. UH 0	, , 0	warfarin NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d470.s1	Caution NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	when WRB 0	TRISENOX NNP B-noun.group	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	other JJ 0	medications NNS B-noun.person	that WDT 0	can MD 0	prolong VB B-verb.creation	the DT 0	QT NNP 0	interval NN 0	( ( 0	e.g. JJ B-adv.all	certain JJ B-adj.all	antiarrhythmics NNS B-noun.attribute	or CC 0	thioridazine NN 0	) ) 0	or CC 0	lead VB B-verb.cognition	to TO 0	electrolyte VB B-verb.social	abnormalities NNS B-noun.person	( ( 0	such JJ 0	as IN 0	diuretics NNS B-noun.person	or CC 0	amphotericin_B JJ B-noun.artifact	) ) 0	. . 0	. . 0
DDI-MedLine.d9.s5	by IN 0	the DT 0	nonlinear JJ B-adj.all	kinetic JJ B-adj.all	characteristics NNS B-noun.act	for IN 0	verapamil NN B-noun.artifact	and CC 0	diltiazem NN B-noun.person	( ( 0	and CC 0	probably RB B-adv.all	for IN 0	nifedipine NN B-noun.person	, , 0	as RB 0	well RB 0	) ) 0	and CC 0	the DT 0	derivative JJ B-adj.all	implications NNS B-noun.motive	for IN 0	decreased VBN B-verb.change	dosing VBG B-verb.body	frequency NN B-noun.person	requirements NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d3.s17	ACE_Inhibitors NNS B-noun.person	, , 0	Concomitant JJ 0	use NN 0	of IN 0	ACE_inhibitors NNS B-noun.object	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	renal JJ B-adj.all	impairment NN B-noun.state	, , 0	particularly RB B-adv.all	in IN 0	volume NN B-noun.artifact	- : 0	depleted VBN B-verb.communication	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d397.s8	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	interactions NNS B-noun.act	of IN 0	erythromycin NN B-noun.food	with IN 0	carbamazepine NN B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	hexobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	alfentanil RB 0	, , 0	cisapride NN 0	, , 0	disopyramide NN 0	, , 0	lovastatin NN B-noun.person	, , 0	bromocriptine NN B-noun.person	, , 0	valproate NN B-noun.attribute	, , 0	terfenadine NN B-noun.person	, , 0	and CC 0	astemizole NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d443.s3	Pyrazolone_Derivatives NNS B-noun.artifact	( ( 0	phenylbutazone NN 0	, , 0	oxyphenbutazone NN 0	, , 0	and CC 0	possibly RB 0	dipyrone VB 0	) ) 0	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.feeling	with IN 0	aspirin NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	gastrointestinal JJ B-adj.all	ulceration NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d9.s0	Azlocillin NNP B-noun.person	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	amikacin NN B-noun.person	, , 0	ciprofloxacin NN B-noun.person	, , 0	gentamicin NN B-noun.person	, , 0	netilmicin NN B-noun.person	, , 0	or CC 0	tobramycin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d521.s1	Before IN 0	taking VBG 0	glimepiride NN B-noun.attribute	, , 0	tell VB B-verb.communication	your PRP$ 0	doctor NN B-noun.person	if IN 0	you PRP 0	are VBP 0	taking VBG B-verb.cognition	any DT 0	of IN 0	the DT 0	following JJ B-adj.all	medicines NNS B-noun.communication	, , 0	; : 0	aspirin NN B-noun.attribute	or CC 0	another DT 0	salicylate NN B-noun.location	such JJ 0	as IN 0	magnesium NN 0	/ : 0	choline_salicylate JJ B-adj.all	( ( 0	Trilisate NNP B-noun.person	) ) 0	, , 0	salsalate NN B-noun.person	( ( 0	Disalcid NNP B-noun.person	, , 0	others NNS 0	) ) 0	, , 0	choline_salicylate JJ B-adj.all	( ( 0	Arthropan NNP B-noun.location	) ) 0	, , 0	magnesium_salicylate JJ B-noun.person	( ( 0	Magan NNP B-noun.person	) ) 0	, , 0	or CC 0	bismuth_subsalicylate JJ B-noun.other	( ( 0	Pepto NNP B-noun.person	- : 0	Bismol NN B-noun.group	) ) 0	, , 0	. . 0
DDI-DrugBank.d332.s1	In IN 0	patients NNS B-noun.person	who WP 0	have VBP 0	received VBN B-verb.possession	muscle_relaxants NNS B-noun.person	, , 0	doxapram NN 0	may MD 0	temporarily RB 0	mask VB B-verb.contact	the DT 0	residual JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	muscle_relaxant_drugs NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d438.s33	Oral NNP B-noun.group	Contraceptive NNP I-noun.group	, , 0	Based VBN B-verb.cognition	on IN 0	AUC NNP B-noun.group	and CC 0	half NN B-noun.person	- : 0	life NN B-noun.time	, , 0	multiple JJ B-noun.person	- : 0	dose RB B-verb.creation	pharmacokinetic JJ B-adj.all	profiles NNS B-noun.shape	of IN 0	norethindrone NN B-noun.person	and CC 0	ethinyl_estradiol NN 0	following VBG B-verb.stative	administration NN B-noun.act	of IN 0	tablets NNS B-noun.artifact	containing VBG B-verb.stative	2.5 CD 0	mg NN B-noun.quantity	of IN 0	norethindrone_acetate JJ B-adj.all	and CC 0	50 CD B-adj.all	mcg NN B-noun.quantity	of IN 0	ethinyl_estradiol NN B-noun.act	were VBD B-verb.stative	similar JJ B-adj.all	with IN 0	and CC 0	without IN 0	coadministration NN B-noun.time	of IN 0	gabapentin NN B-noun.substance	( ( 0	400 CD 0	mg IN 0	TID NNP 0	, , 0	. . 0
DDI-DrugBank.d411.s3	Binding VBG B-verb.social	to TO 0	Serum NNP B-noun.person	Proteins NNPS I-noun.person	, , 0	The DT 0	following VBG 0	agents NNS B-noun.person	may MD 0	either CC 0	inhibit VB B-verb.social	levothyroxine_sodium NN B-noun.state	binding VBG B-verb.social	to TO 0	serum VB B-verb.social	proteins NNS B-noun.possession	or CC 0	alter VB B-verb.change	the DT 0	concentrations NNS B-noun.cognition	of IN 0	serum NN B-noun.substance	binding JJ B-adj.pert	proteins NNS B-noun.person	, , 0	androgens NNS B-noun.person	and CC 0	related VBN B-verb.stative	anabolic_hormones NNS 0	, , 0	asparaginase NN B-noun.person	, , 0	clofibrate NN B-noun.person	, , 0	estrogens NNS B-noun.artifact	and CC 0	estrogen NN B-noun.person	- : 0	containing_compounds NNS B-noun.other	, , 0	5-fluorouracil NN 0	, , 0	furosemide RB 0	, , 0	glucocorticoids NNS B-noun.person	, , 0	meclofenamic_acid JJ 0	, , 0	mefenamic_acid JJ 0	, , 0	methadone NN B-noun.person	, , 0	perphenazine NN B-noun.person	, , 0	phenylbutazone NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	salicylates NNS B-noun.person	, , 0	tamoxifen NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d220.s5	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Mefloquine NNP B-noun.person	and CC 0	other JJ 0	related JJ B-adj.all	compounds NNS B-noun.person	( ( 0	eg UH 0	, , 0	quinine NN B-noun.location	, , 0	quinidine NN B-noun.location	and CC 0	chloroquine NN B-noun.body	) ) 0	may MD 0	produce VB B-verb.change	electrocardiographic JJ B-adj.all	abnormalities NNS B-noun.person	and CC 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	convulsions NNS B-noun.food	. . 0	. . 0
DDI-MedLine.d133.s0	Suppression NN B-noun.person	by IN 0	verapamil NN B-noun.time	of IN 0	bombesin NN B-noun.food	- : 0	enhanced VBN B-verb.communication	peritoneal JJ B-noun.person	metastasis NN I-noun.person	of IN 0	intestinal JJ B-adj.all	adenocarcinomas NNS B-noun.communication	induced VBN B-verb.creation	by IN 0	azoxymethane NN B-noun.person	in IN 0	wistar NN B-noun.animal	rats NNS I-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d56.s0	Taking VBG 0	amyl_nitrite JJ 0	after IN 0	drinking VBG B-verb.consumption	alcohol NN B-noun.food	may MD 0	worsen VB B-verb.emotion	side JJ 0	effects NNS B-noun.phenomenon	and CC 0	may MD 0	cause VB B-verb.cognition	severe JJ 0	hypotension NN 0	and CC 0	cardiovascular JJ B-adj.all	collapse NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d224.s0	Apraclonidine NNP B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	MAO_inhibitors NNS B-noun.person	.. . 0	. . 0
DDI-MedLine.d56.s1	Palytoxin NNP B-noun.person	( ( 0	PTX NNP 0	) ) 0	, , 0	C129H223N3O54 NNP B-noun.person	, , 0	isolated VBN B-verb.change	from IN 0	marine JJ B-adj.all	coelenterates NNS B-noun.event	of IN 0	Palythoa NNP B-noun.person	tuberculosa NN I-noun.person	, , 0	caused VBD B-verb.communication	a DT 0	first JJ B-adj.all	rapid JJ B-adj.all	contraction NN 0	followed VBN B-verb.stative	by IN 0	the DT 0	slow JJ B-adj.all	phasic JJ B-adj.all	contraction NN B-noun.event	of IN 0	guinea NN B-noun.person	- : 0	pig NN B-noun.person	vas VBD B-verb.stative	deferens NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s1	CNS NNS B-noun.group	- : 0	Active JJ B-noun.person	Drugs NNP I-noun.person	Ethanol NNP I-noun.person	, , 0	Sonata NNP B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	potentiated VBD B-verb.stative	the DT 0	CNS NNP B-noun.group	- : 0	impairing JJ B-verb.communication	effects NNS B-noun.phenomenon	of IN 0	ethanol NN 0	0.75 CD 0	g PRP 0	/ : 0	kg PRP 0	on IN 0	balance NN B-noun.possession	testing NN I-noun.possession	and CC 0	reaction NN B-noun.process	time NN B-noun.time	for IN 0	1 CD B-adj.all	hour NN B-noun.communication	after IN 0	ethanol JJ B-adj.all	administration NN B-noun.person	and CC 0	on IN 0	the DT 0	digit JJ B-adj.all	symbol NN 0	substitution NN 0	test NN 0	( ( 0	DSST NNP 0	) ) 0	, , 0	symbol NN 0	copying NN 0	test NN 0	, , 0	and CC 0	the DT 0	variability NN B-noun.phenomenon	component NN B-noun.artifact	of IN 0	the DT 0	divided VBN 0	attention NN 0	test NN 0	for IN 0	2.5 CD 0	hours NNS B-noun.quantity	after IN 0	ethanol JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d172.s11	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	post NN B-adj.all	marketing NN B-noun.act	observations NNS B-noun.act	, , 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s17	Carbamazepine NNP B-noun.person	, , 0	Felbatol NNP B-noun.person	_ , 0	causes VBZ B-verb.communication	a DT 0	decrease NN B-noun.event	in IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	carbamazepine NN 0	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	and CC 0	an DT 0	increase NN B-noun.act	in IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	carbamazepine_epoxide JJ 0	plasma NN B-noun.substance	concentration NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d480.s10	The DT 0	administration NN B-noun.time	of IN 0	epinephrine NN B-noun.location	should MD 0	be VB 0	avoided VBN B-verb.social	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	drug NN B-noun.phenomenon	induced VBN B-verb.creation	hypotension NN 0	because IN 0	of IN 0	a DT 0	possible JJ B-adj.all	reverse NN B-noun.phenomenon	epinephrine NN B-noun.phenomenon	effect NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d124.s19	No DT 0	data NNS B-noun.cognition	are VBP B-verb.stative	available JJ B-adj.all	for IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	INVIRASE NNP B-noun.group	/ POS 0	ritonavir NN B-noun.person	or CC 0	FORTOVASE NNP B-noun.group	/ POS 0	ritonavir NN B-noun.person	and CC 0	garlic JJ B-adj.all	capsules NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d307.s16	Influence NN B-noun.cognition	of IN 0	Trileptal NNP B-noun.person	on IN 0	AED NNP B-noun.group	Concentration NNP I-noun.group	( ( 0	Mean JJ 0	change NN 0	, , 0	90 CD B-adj.all	% NN 0	Confidence NNP B-noun.group	Interval NNP I-noun.group	) ) 0	. . 0
DDI-DrugBank.d8.s0	Both DT 0	the DT 0	magnitude NN B-noun.person	and CC 0	duration NN B-noun.act	of IN 0	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.cognition	and CC 0	cardiovascular JJ B-adj.all	effects NNS B-noun.phenomenon	may MD 0	be VB 0	enhanced VBN B-verb.change	when WRB 0	ALFENTA NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	other JJ 0	CNS_depressants NNS 0	such JJ 0	as IN 0	barbiturates NNS B-noun.artifact	, , 0	tranquilizers NNS B-noun.person	, , 0	opioids NNS B-noun.person	, , 0	or CC 0	inhalation NN B-noun.possession	general JJ B-adj.all	anesthetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s16	In IN 0	a DT 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trial NN B-noun.cognition	, , 0	a DT 0	20 CD B-adj.all	% NN 0	reduction NN B-noun.act	of IN 0	the DT 0	phenytoin NN B-noun.person	dose NN B-noun.person	at IN 0	the DT 0	initiation NN B-noun.act	of IN 0	Felbatol NNP B-noun.person	_ ( 0	therapy NN B-noun.person	resulted VBD B-verb.stative	in IN 0	phenytoin NN B-noun.animal	levels NNS B-noun.attribute	comparable JJ 0	to TO 0	those DT 0	prior JJ B-adj.all	to TO 0	Felbatol NNP B-noun.person	_ , 0	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d543.s7	Because IN 0	antacids NNS B-noun.animal	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	anticholinergic_agents NNS B-noun.location	, , 0	simultaneous JJ B-adj.all	use NN B-noun.act	of IN 0	these DT 0	drugs NNS B-noun.artifact	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d5.s4	In IN 0	ewes NNS 0	given VBN B-verb.possession	40 CD B-adj.all	mg NN B-noun.quantity	of IN 0	phenobarbital_sodium NN B-noun.time	/ '' 0	kg PRP 0	for IN 0	5 CD B-adj.all	days NNS B-noun.person	intraperitoneally RB B-adv.all	( ( 0	IP NNP 0	) ) 0	, , 0	the DT 0	anticholinesterase JJ B-adj.all	effect NN B-noun.cognition	of IN 0	4 CD B-adj.all	mg NN B-noun.quantity	of IN 0	coumaphos NNS B-noun.communication	/ : 0	kg PRP 0	was VBD B-verb.stative	significantly RB B-adv.all	reduced VBN B-verb.change	and CC 0	signs NNS B-noun.communication	of IN 0	toxicity NN B-noun.state	were VBD B-verb.stative	not RB B-adv.all	present JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d337.s2	There EX 0	were VBD B-verb.stative	no DT 0	reports NNS B-noun.communication	of IN 0	skeletal JJ B-adj.pert	myopathy NN B-noun.state	in IN 0	a DT 0	placebo NN B-noun.person	- : 0	controlled JJ B-verb.social	Phase NN B-noun.person	I PRP 0	trial VBP B-verb.social	in IN 0	which WDT 0	10 CD B-adj.all	healthy JJ B-adj.all	subjects NNS B-noun.person	on IN 0	stable JJ B-adj.all	simvastatin NN B-noun.person	therapy NN B-noun.person	were VBD 0	treated VBN B-verb.change	concurrently RB B-adv.all	with IN 0	daptomycin NN B-noun.person	( ( 0	4 CD 0	mg FW 0	/ FW 0	kg FW 0	once RB 0	every DT 0	24 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	for IN 0	14 CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d422.s9	The DT 0	onset NN B-noun.event	of IN 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	by IN 0	succinylcholine NN B-noun.person	was VBD B-verb.stative	unaffected JJ B-adj.all	by IN 0	BREVIBLOC NNP B-noun.person	, , 0	but CC 0	the DT 0	duration NN 0	of IN 0	neuromuscular JJ B-adj.all	blockade NN B-noun.location	was VBD 0	prolonged VBN B-verb.creation	from IN 0	5 CD B-adj.all	minutes NNS B-noun.time	to TO 0	8 CD B-adj.all	minutes NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d188.s2	however RB 0	, , 0	it PRP 0	adversely RB B-adv.all	affected VBN B-verb.change	response NN 0	duration NN 0	suggesting VBG B-verb.communication	that IN 0	pyridoxine NN 0	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	with IN 0	HEXALEN NNP B-noun.group	and/or CC I-noun.group	cisplatin.1 NN I-noun.group	. . 0
DDI-DrugBank.d212.s13	Effect NN 0	of IN 0	AEDs NNP B-noun.person	in IN 0	Pediatric NNP B-noun.group	Patients NNPS I-noun.group	There EX 0	was VBD B-verb.stative	about IN 0	a DT 0	22 CD B-adj.all	% NN 0	increase NN B-noun.event	of IN 0	apparent JJ B-adj.all	total NN 0	body NN 0	clearance NN B-noun.attribute	of IN 0	levetiracetam NN B-noun.attribute	when WRB 0	it PRP 0	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	enzyme NN B-noun.person	- : 0	inducing VBG B-verb.communication	AEDs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d316.s17	Tacrolimus NNP B-noun.person	_ NNP I-noun.person	Felodipine NNP I-noun.person	may MD 0	increase VB B-verb.change	the DT 0	blood NN B-noun.act	concentration NN B-noun.event	of IN 0	tacrolimus NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d357.s4	Patients NNS B-noun.person	with IN 0	major JJ B-adj.all	psychotic JJ B-adj.pert	disorders NNS B-noun.person	, , 0	treated VBN B-verb.change	with IN 0	neuroleptics NNS B-noun.person	, , 0	should MD 0	be VB 0	treated VBN B-verb.change	with IN 0	dopamine_agonists NNS B-noun.person	only RB B-adv.all	if IN 0	the DT 0	potential JJ B-adj.all	benefits NNS B-noun.person	outweigh VBP B-verb.communication	the DT 0	risks NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d198.s4	Cimetidine NNP B-noun.person	( ( 0	400 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	) ) 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	vardenafil NN B-noun.artifact	bioavailability NN I-noun.artifact	( ( 0	AUC NNP 0	) ) 0	and CC 0	maximum JJ B-adj.all	concentration NN B-noun.cognition	( ( 0	Cmax NNP B-noun.person	) ) 0	of IN 0	vardenafil NN B-noun.time	when WRB 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	20 CD 0	mg DT 0	Vardenafil NNP B-noun.person	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d158.s13	Ethosuximide NNP B-noun.person	, , 0	Amphetamines NNPS B-noun.person	may MD 0	delay VB B-verb.stative	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	ethosuximide NN 0	. . 0	. . 0
DDI-DrugBank.d307.s5	The DT 0	inhibition NN B-noun.attribute	of IN 0	CYP-2C19 NNP B-noun.person	by IN 0	OXC NNP 0	and CC 0	MHD NNP B-noun.group	, , 0	however RB 0	, , 0	is VBZ B-verb.stative	clinically RB B-adv.all	relevant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d561.s4	Potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	( ( 0	spironolactone NN 0	, , 0	amiloride IN 0	, , 0	triamterene NN B-noun.person	, , 0	and CC 0	others NNS 0	) ) 0	or CC 0	potassium NN B-noun.person	supplements NNS B-noun.person	can MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	hyperkalemia NN B-noun.person	. . 0	. . 0
DDI-MedLine.d39.s8	These DT 0	results NNS B-noun.communication	, , 0	together RB 0	with IN 0	the DT 0	known JJ B-adj.all	relationships NNS B-noun.body	between IN 0	estrogen NN B-noun.person	and CC 0	the DT 0	immune JJ B-adj.all	response NN B-noun.communication	, , 0	suggest VBP B-verb.communication	that IN 0	estrogens NNS B-noun.animal	affect VBP B-verb.change	the DT 0	course NN B-noun.location	of IN 0	septic JJ B-adj.all	shock NN B-noun.event	in IN 0	a DT 0	complex JJ B-adj.all	fashion NN B-noun.act	and CC 0	may MD 0	have VB B-verb.change	either CC 0	protective JJ B-adj.all	or CC 0	deleterious JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d158.s18	Norepinephrine NNP B-noun.person	, , 0	Amphetamines NNS B-noun.person	enhance VBP B-verb.change	the DT 0	adrenergic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	norepinephrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d120.s1	anticholinergics NNS B-noun.attribute	or CC 0	other JJ B-adj.all	medications NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	; : 0	anticholinergic JJ B-adj.all	effects NNS B-noun.phenomenon	may MD 0	be VB 0	potentiated VBN B-verb.cognition	when WRB 0	these DT 0	medications NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	diphenidol NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d433.s2	Also RB B-adv.all	, , 0	the DT 0	potential NN B-noun.person	for IN 0	hepatic JJ B-adj.all	injury NN B-noun.attribute	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	Rebif NNP B-noun.person	_ ( 0	is VBZ 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	other JJ 0	products NNS B-noun.person	associated VBN B-verb.cognition	with IN 0	hepatic JJ B-adj.all	injury NN B-noun.event	, , 0	or CC 0	when WRB 0	new JJ B-adj.all	agents NNS B-noun.person	are VBP 0	added VBN B-verb.change	to TO 0	the DT 0	regimen NNS B-noun.person	of IN 0	patients NNS B-noun.person	already RB B-adv.all	on IN 0	Rebif NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d165.s6	Based VBN B-verb.cognition	on IN 0	the DT 0	chemical NN B-noun.body	resemblance NN B-noun.act	of IN 0	itraconazole NN B-noun.artifact	and CC 0	ketoconazole NN B-noun.person	, , 0	coadministration NN B-noun.person	of IN 0	astemizole NN B-noun.location	with IN 0	itraconazole NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d98.s0	Behavioral JJ B-adj.all	responses NNS B-noun.motive	to TO 0	repeated VBN B-verb.communication	cocaine NN B-noun.person	exposure NN B-noun.person	in IN 0	mice NNS B-noun.animal	selectively RB B-adv.all	bred VBN B-verb.social	for IN 0	differential JJ B-adj.all	sensitivity NN B-noun.feeling	to TO 0	pentobarbital JJ B-adj.all	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d450.s14	Furthermore RB B-adv.all	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	combining VBG B-verb.creation	digoxin NN I-verb.creation	with IN 0	any DT 0	drug NN B-noun.group	that WDT 0	may MD 0	cause VB B-verb.communication	a DT 0	significant JJ B-adj.all	deterioration NN B-noun.cognition	in IN 0	renal JJ B-adj.all	function NN B-noun.act	, , 0	since IN 0	a DT 0	decline NN B-noun.person	in IN 0	glomerular JJ B-adj.all	filtration NN B-noun.communication	or CC 0	tubular JJ B-adj.all	secretion NN B-noun.act	may MD 0	impair VB B-verb.change	the DT 0	excretion NN B-noun.act	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d105.s7	Azithromycin NNP B-noun.person	had VBD B-verb.social	no DT 0	significant JJ B-adj.all	impact NN B-noun.state	on IN 0	the DT 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	zidovudine NN B-noun.person	, , 0	although IN 0	it PRP 0	significantly RB B-adv.all	decreased VBD B-verb.change	the DT 0	zidovudine JJ B-adj.all	tmax NN B-noun.person	by IN 0	44 CD 0	% NN 0	and CC 0	increased VBD B-verb.change	the DT 0	intracellular JJ B-adj.all	exposure NN B-noun.communication	to TO 0	phosphorylated JJ B-verb.communication	zidovudine NN B-noun.person	by IN 0	110 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d340.s6	Drugs NNS B-noun.other	That WDT I-noun.other	Should MD I-noun.other	Not RB I-noun.other	Be VB I-noun.other	Coadministered NNP I-noun.other	With IN I-noun.other	VIRACEPT NNP I-noun.other	Antiarrhythmics NNPS I-noun.other	, , 0	amiodarone NN 0	, , 0	quinidine JJ B-adj.all	Antihistamines NNP B-noun.location	, , 0	astemizole NN B-noun.location	, , 0	terfenadine NN 0	Antimigraine NNP B-noun.location	, , 0	ergot_derivatives VBZ B-verb.creation	Antimycobacterial_agents NNS I-verb.creation	, , 0	rifampin NN B-noun.person	Benzodiazepines NNP I-noun.person	midazolam NN I-noun.person	, , 0	triazolam NN 0	GI NNP 0	motility NN 0	agents NNS B-noun.person	, , 0	cisapride NN 0	. . 0
DDI-DrugBank.d195.s9	Estrogen SYM 0	- : 0	containing VBG B-verb.cognition	therapies NNS B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	with IN 0	ARIMIDEX NNP B-noun.group	as IN 0	they PRP 0	may MD 0	diminish VB B-verb.change	its PRP$ 0	pharmacologic JJ B-adj.pert	action NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d174.s1	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	administering VBG B-verb.creation	nabumetone NN I-verb.creation	with IN 0	warfarin NN 0	since IN 0	interactions NNS B-noun.act	have VBP 0	been VBN 0	seen VBN B-verb.perception	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d481.s0	Milk NN B-noun.person	, , 0	milk NN B-noun.body	products NNS I-noun.body	, , 0	and CC 0	calcium NN B-noun.person	- : 0	rich JJ B-adj.all	foods NNS B-noun.food	or CC 0	drugs NNS B-noun.animal	may MD 0	impair VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	EMCYT NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d400.s0	Aspirin NNP B-noun.person	, , 0	As IN 0	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Ponstel NNP B-noun.location	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	generally RB B-adv.all	recommended VBN B-verb.communication	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	of IN 0	increased VBN B-verb.change	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d176.s6	Lithium NNP B-noun.person	, , 0	Increased VBD B-verb.change	serum NN B-noun.body	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	symptoms NNS B-noun.communication	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ACE_inhibitors NNS B-noun.person	during IN 0	therapy NN 0	with IN 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d318.s2	Corticosteroids NNS B-noun.person	and CC 0	Corticotropin NNP B-noun.person	( ( 0	ACTH NNP 0	) ) 0	, , 0	may MD 0	potentiate VB B-verb.stative	amphotericin_B- JJ 0	induced VBN B-verb.creation	hypokalemia NN 0	which WDT 0	may MD 0	predispose VB B-verb.creation	the DT 0	patient NN B-noun.person	to TO 0	cardiac VB B-verb.social	dysfunction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d340.s4	Coadministration NN B-noun.person	of IN 0	VIRACEPT NNP B-noun.group	and CC 0	drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	CYP3A NNP I-verb.stative	may MD 0	increase VB B-verb.change	nelfinavir JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d29.s12	Therefore RB 0	, , 0	esomeprazole NN B-noun.communication	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	drugs NNS B-noun.artifact	where WRB 0	gastric JJ B-adj.all	pH NN B-noun.attribute	is VBZ B-verb.stative	an DT 0	important JJ B-adj.all	determinant NN B-noun.cognition	of IN 0	bioavailability NN B-noun.cognition	( ( 0	eg UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	iron NN B-noun.person	salts NNS B-noun.substance	and CC 0	digoxin NN B-noun.act	) ) 0	. . 0	. . 0
DDI-DrugBank.d87.s19	Because IN 0	both DT 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	have VBP B-verb.change	negative JJ B-adj.all	inotropic NN B-noun.phenomenon	properties NNS B-noun.attribute	and CC 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	coadministration NN B-noun.person	with IN 0	TAMBOCOR NNP B-noun.group	are VBP B-verb.stative	unknown JJ B-adj.all	, , 0	neither CC 0	disopyramide VB B-verb.communication	nor CC 0	verapamil NN B-noun.artifact	should MD 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	TAMBOCOR NNP B-noun.group	unless IN 0	, , 0	in IN 0	the DT 0	judgment NN B-noun.person	of IN 0	the DT 0	physician NN B-noun.communication	, , 0	the DT 0	benefits NNS B-noun.person	of IN 0	this DT 0	combination NN B-noun.event	outweigh VBP B-verb.stative	the DT 0	risks NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d318.s8	Imidazoles NNP B-noun.person	( ( 0	e. FW 0	g. FW 0	, , 0	ketoconazole NN B-noun.person	, , 0	miconazole NN B-noun.person	, , 0	clotrimazole NN B-noun.person	, , 0	fluconazole NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	, , 0	in IN 0	vitro NN B-noun.animal	and CC 0	animal NN B-noun.object	studies NNS I-noun.object	with IN 0	the DT 0	combination NN B-noun.event	of IN 0	amphotericin_B JJ B-noun.possession	and CC 0	imidazoles NNS B-noun.act	suggest VBP B-verb.communication	that IN 0	imidazoles NNS B-noun.act	may MD 0	induce VB B-verb.cognition	fungal JJ B-adj.all	resistance NN B-noun.phenomenon	to TO 0	amphotericin_B. VB B-verb.motion	. . 0
DDI-DrugBank.d141.s0	Immunosuppressive_Drugs NNS B-noun.artifact	, , 0	Fibric_Acid_Derivatives NNS B-noun.body	, , 0	Niacin NNP B-noun.person	( ( I-noun.person	Nicotinic_Acid JJ I-noun.person	, , 0	Erythromycin NNP B-noun.person	, , 0	Azole_Antifungals NNS B-noun.person	, , 0	Skeletal NNP B-noun.location	Muscle NNP I-noun.location	. . 0	. . 0
DDI-MedLine.d34.s1	The DT 0	effects NNS B-noun.phenomenon	of IN 0	supplementary JJ B-adj.all	oral JJ B-adj.all	cobalt NN B-noun.person	and CC 0	iron NN B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	the DT 0	interaction NN B-noun.act	between IN 0	both DT 0	at IN 0	the DT 0	absorption NN B-noun.artifact	site NN 0	, , 0	fecal JJ B-adj.all	and CC 0	urinary JJ B-adj.all	excretion NN B-noun.act	as RB 0	well RB 0	as IN 0	the DT 0	retention NN B-noun.act	of IN 0	these DT 0	trace NN B-noun.location	elements NNS B-noun.person	were VBD 0	determined VBN B-verb.communication	by IN 0	using VBG B-verb.consumption	four CD 0	diets NNS B-noun.artifact	containing VBG B-verb.communication	either CC 0	9 CD B-adj.all	or CC 0	63 CD 0	micrograms NNS B-noun.quantity	/ : 0	kg NN B-noun.quantity	of IN 0	Co NNP B-noun.person	and CC 0	48 CD 0	or CC 0	446 CD 0	mg NN B-noun.quantity	/ CD 0	kg NN B-noun.quantity	of IN 0	Fe NNP 0	over IN 0	a DT 0	period NN B-noun.time	of IN 0	19 CD B-adj.all	days NNS B-noun.person	in IN 0	a DT 0	total NN B-noun.state	of IN 0	24 CD B-adj.all	rats NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d61.s0	Pharmacokinetic JJ B-adj.all	evaluation NN B-noun.act	of IN 0	the DT 0	digoxin NN B-noun.person	- : 0	amiodarone NN 0	interaction NN B-noun.act	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d359.s3	Presumably RB B-adv.all	, , 0	phenytoin NN B-noun.person	acts VBZ B-verb.stative	as IN 0	a DT 0	stimulator NN B-noun.artifact	of IN 0	coumarin NN B-noun.group	metabolism NN B-noun.attribute	and CC 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	cause VB B-verb.communication	decreased VBN B-verb.change	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	the DT 0	coumarin_anticoagulants NNS B-noun.group	and CC 0	increased VBD B-verb.change	prothrombin NN B-noun.person	- : 0	proconvertin NN B-noun.person	concentrations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d314.s25	Aspirin NNP B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	conjunction NN 0	with IN 0	corticosteroids NNS B-noun.food	in IN 0	hypoprothrombinemia NN 0	. . 0	. . 0
DDI-DrugBank.d198.s37	Upon IN 0	administration NN B-noun.time	of IN 0	10 CD B-adj.all	mg NN B-noun.quantity	of IN 0	Vardenafil NNP B-noun.person	with IN 0	800 CD 0	mg IN 0	TID NNP 0	indinavir NN 0	, , 0	the DT 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	indinavir NN B-noun.person	were VBD 0	reduced VBN B-verb.change	by IN 0	40 CD B-adj.all	% NN 0	and CC 0	30 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-MedLine.d13.s7	On IN 0	the DT 0	basis NN B-noun.cognition	of IN 0	the DT 0	estimated JJ B-adj.all	number NN B-noun.quantity	of IN 0	regular JJ B-adj.all	users NNS B-noun.person	of IN 0	intravenous JJ B-adj.all	amphetamine NN B-noun.person	in IN 0	Ontario NNP B-noun.other	, , 0	the DT 0	mortality NN B-noun.attribute	rate NN B-noun.time	in IN 0	such JJ B-adj.all	users NNS B-noun.person	is VBZ B-verb.stative	at IN 0	least JJS 0	four CD 0	times NNS 0	as RB 0	high JJ 0	as IN 0	in IN 0	the DT 0	general JJ B-adj.all	population NN B-noun.cognition	of IN 0	the DT 0	same JJ B-adj.all	age NN B-noun.person	, , 0	and CC 0	is VBZ B-verb.stative	comparable JJ B-adj.all	to TO 0	that DT 0	in IN 0	alcoholics NNS B-noun.animal	and CC 0	heroin NN B-noun.person	addicts NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d263.s24	Metoclopramide NNP B-noun.person	, , 0	Bioavailability NNP B-noun.person	is VBZ B-verb.stative	mildly RB B-adv.all	reduced VBN B-verb.change	( ( 0	approximately RB B-adv.all	10 CD B-adj.all	% NN 0	) ) 0	when WRB 0	zalcitabine NN B-noun.person	and CC 0	metoclopramide NN B-noun.attribute	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d274.s2	Preliminary JJ B-adj.all	studies NNS B-noun.act	indicate VBP B-verb.communication	that IN 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	dobutamine NN B-noun.act	and CC 0	nitroprusside JJ B-adj.all	results NNS B-noun.substance	in IN 0	a DT 0	higher JJR B-adj.all	cardiac JJ B-noun.person	output NN I-noun.person	and CC 0	, , 0	usually RB B-adv.all	, , 0	a DT 0	lower JJR B-adj.all	pulmonary JJ B-adj.all	wedge NN B-noun.phenomenon	pressure NN I-noun.phenomenon	than IN 0	when WRB 0	either DT 0	drug NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	alone RB 0	. . 0	. . 0
DDI-MedLine.d23.s0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	ketamine NN B-noun.person	and CC 0	of IN 0	Innovar JJ B-adj.all	anesthesia NN 0	on IN 0	digitalis NN 0	tolerance NN 0	in IN 0	dogs NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d198.s34	The DT 0	administration NN B-noun.time	of IN 0	lower JJR B-adj.all	doses NNS B-noun.person	of IN 0	Vardenafil NNP B-noun.person	with IN 0	alpha NN B-noun.feeling	- : 0	blockers NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	completely RB B-adv.all	evaluated VBN B-verb.cognition	to TO 0	determine VB B-verb.communication	if IN 0	they PRP 0	can MD 0	be VB 0	safely RB B-adv.all	administered VBN B-verb.body	together RB B-adv.all	. . 0	. . 0
DDI-MedLine.d110.s13	Ibogaine NNP B-noun.person	, , 0	but CC 0	not RB B-adv.all	18-MC JJ 0	, , 0	decreases VBZ B-verb.change	heart NN B-noun.body	rate NN B-noun.time	at IN 0	high JJ B-adj.all	doses NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d422.s2	A DT 0	study NN B-noun.artifact	of IN 0	interaction NN B-noun.act	between IN 0	BREVIBLOC NNP B-noun.person	and CC 0	warfarin NN B-noun.person	showed VBD B-verb.communication	that IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	BREVIBLOC NNP B-noun.group	and CC 0	warfarin NN B-noun.communication	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	warfarin NN B-noun.act	plasma NN I-noun.act	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d522.s12	Theophylline PRP 0	, , 0	Following VBG 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	two CD 0	250-mg JJ 0	dirithromycin NN B-noun.substance	tablets NNS B-noun.artifact	administered VBN B-verb.communication	once RB B-adv.all	daily RB 0	with IN 0	200-mg JJ 0	theophylline NN 0	tablets NNS B-noun.artifact	administered VBD B-verb.communication	twice RB I-verb.communication	daily RB 0	for IN 0	10 CD B-adj.all	days NNS B-noun.time	to TO 0	14 CD B-adj.all	healthy JJ B-adj.all	subjects NNS B-noun.person	, , 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	theophylline PRP 0	was VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d231.s2	Furosemide NN 0	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	ethacrynic_acid JJ 0	because IN 0	of IN 0	the DT 0	possibility NN B-noun.state	of IN 0	ototoxicity NN 0	. . 0	. . 0
DDI-DrugBank.d139.s6	Orlistat NNP B-noun.person	- : 0	Orlistat NNP B-noun.group	may MD 0	decrease VB B-verb.cognition	the DT 0	absorption NN B-noun.artifact	of IN 0	vitamin_K. NNP B-noun.person	. . 0
DDI-DrugBank.d384.s13	Vitamin_D NN B-noun.artifact	, , 0	The DT 0	coadministration NN B-noun.person	of IN 0	any DT 0	of IN 0	the DT 0	vitamin_D_analogues NNS B-noun.plant	should MD 0	be VB 0	avoided VBN B-verb.social	as IN 0	this DT 0	could MD 0	create VB B-verb.perception	possible JJ B-adj.all	additive JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	hypercalcemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d123.s11	Non SYM 0	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	but CC 0	not RB B-adv.all	aspirin VB B-verb.social	) ) 0	, , 0	These DT 0	drugs NNS B-noun.artifact	in IN 0	combination NN 0	with IN 0	very RB B-adv.all	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	quinolones NNS B-noun.communication	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	provoke VB B-verb.creation	convulsions NNS B-noun.food	in IN 0	pre SYM 0	- : 0	clinical JJ B-adj.all	studies NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d87.s12	TAMBOCOR NNP B-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	in IN 0	a DT 0	large JJ B-adj.all	number NN B-noun.quantity	of IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	diuretics NNS B-noun.person	without IN 0	apparent JJ B-adj.all	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d332.s0	Administration NN B-noun.person	of IN 0	doxapram NN 0	to TO 0	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.change	sympathomimetic JJ B-adj.all	or CC 0	monoamine_oxidase_inhibiting_drugs NNS B-noun.substance	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	additive JJ B-adj.all	pressor NN B-noun.person	effect NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d339.s0	Carbamazepine NNP B-noun.person	, , 0	Elevated NNP B-noun.person	carbamazepine NN I-noun.person	levels NNS B-noun.attribute	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	postmarketing VBG B-verb.communication	experience NN B-noun.event	when WRB 0	SUPRAX NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d543.s0	The DT 0	following VBG 0	agents NNS B-noun.person	may MD 0	increase VB B-verb.change	certain JJ B-adj.all	actions NNS B-noun.act	or CC 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	anticholinergic_drugs NNS B-noun.object	. . 0	amantadine VB B-verb.stative	antiarrhythmic_agents NNS B-noun.event	of IN 0	class NN B-noun.attribute	( ( 0	e.g. JJ B-adj.all	quinidine NN B-noun.location	) ) 0	, , 0	antihistamines VBZ B-verb.cognition	antipsychotic_agents NNS B-noun.attribute	( ( 0	e.g. JJ B-adj.all	phenothiazines NNS B-noun.artifact	) ) 0	, , 0	benzodiazepines NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d438.s15	Naproxen NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	( ( 0	N=18 NN 0	) ) 0	of IN 0	naproxen_sodium NN B-noun.artifact	capsules NNS I-noun.artifact	( ( 0	250 CD 0	mg NN B-noun.quantity	) ) 0	with IN 0	Neurontin NNP B-noun.person	( ( 0	125 CD 0	mg NN B-noun.quantity	) ) 0	appears VBZ B-verb.stative	to TO 0	increase VB B-verb.change	the DT 0	amount NN B-noun.possession	of IN 0	gabapentin NN B-noun.substance	absorbed VBN B-verb.contact	by IN 0	12 CD B-adj.all	% NN 0	to TO 0	15 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d76.s8	NaCMC FW 0	at IN 0	1 CD B-adj.all	% NN 0	( ( 0	m UH 0	/ : 0	v LS 0	) ) 0	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	free JJ B-noun.person	cysteine NN I-noun.person	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	R NNP 0	- : 0	value NN B-noun.attribute	of IN 0	NaFlu NNP B-noun.person	compared VBN B-verb.communication	to TO 0	NaCMC VB B-verb.stative	alone RB I-verb.stative	. . 0	. . 0
DDI-DrugBank.d314.s26	The DT 0	clearance NN B-noun.attribute	of IN 0	salicylates NNS B-noun.substance	may MD 0	be VB 0	increased VBN B-verb.change	with IN 0	concurrent JJ B-adj.all	use NN 0	of IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d427.s5	Quinolones NNS B-noun.communication	, , 0	including VBG B-verb.change	nalidixic_acid JJ I-verb.change	, , 0	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	oral JJ B-adj.all	anticoagulant JJ B-adj.all	warfarin NN B-noun.communication	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d53.s5	Concurrent JJ B-adj.all	use NN 0	of IN 0	macrolides NNS B-noun.person	and CC 0	warfarin NN B-noun.act	in IN 0	clinical JJ B-adj.all	practice NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	increased VBN B-verb.change	anticoagulant JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d76.s5	Unmodified JJ B-noun.group	NaCMC NNP I-noun.group	( ( 0	1 CD B-adj.all	% NN 0	m IN 0	/ : 0	v LS 0	) ) 0	significantly RB B-adv.all	improved VBD B-verb.change	the DT 0	transport NN B-noun.body	ratio NN B-noun.time	( ( 0	R= : 0	P(app LS 0	) ) 0	polymer/ NN B-noun.quantity	P(app NN B-noun.location	) ) 0	control NN B-noun.act	) ) 0	of IN 0	NaFlu NNP B-noun.person	to TO 0	1.3 CD 0	and CC 0	1 CD B-adj.all	% NN 0	( ( 0	m UH 0	/ : 0	v LS 0	) ) 0	NaCMC FW 0	conjugated VBN B-verb.communication	with IN 0	cysteine NN 0	further RB B-adv.all	enhanced VBD B-verb.change	the DT 0	permeation NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d43.s4	Antacids NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	antacids NNS B-noun.substance	containing VBG B-verb.stative	magnesium NN B-noun.substance	or CC 0	aluminum NN B-noun.person	with IN 0	VIDEX NNP B-noun.group	Chewable NNP I-noun.group	/ NNP I-noun.group	Dispersible NNP I-noun.group	Buffered NNP I-noun.group	Tablets NNPS I-noun.group	or CC 0	Pediatric NNP B-noun.person	Powder NNP I-noun.person	for IN 0	Oral NNP B-noun.location	Solution NNP I-noun.location	may MD 0	potentiate VB B-verb.cognition	adverse JJ 0	events NNS 0	associated VBN B-verb.cognition	with IN 0	the DT 0	antacid JJ B-adj.all	components NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d43.s6	Ganciclovir NNP B-noun.person	, , 0	Administration NNP B-noun.person	of IN 0	VIDEX NNP B-noun.group	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	or CC 0	concurrent JJ B-adj.all	with IN 0	oral JJ B-adj.all	ganciclovir NN B-noun.person	was VBD 0	associated VBN B-verb.cognition	with IN 0	a DT 0	111 CD 0	( ( 0	114)% JJ 0	increase NN B-noun.event	in IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	AUC NNP 0	of IN 0	didanosine NN B-noun.person	( ( 0	n UH 0	= $ 0	12 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d307.s7	Increases NNS B-noun.event	of IN 0	22 CD B-adj.all	% NN 0	with IN 0	MHD NNP B-noun.group	and CC 0	47 CD B-adj.all	% NN 0	with IN 0	oxcarbazepine NN B-noun.person	were VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d468.s10	When WRB 0	therapeutic JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	furosemide NN B-noun.location	, , 0	propranolol NN B-noun.person	, , 0	dipyridamole NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	quinidine NN B-noun.location	, , 0	or CC 0	naproxen NNS B-noun.person	were VBD 0	added VBN B-verb.change	to TO 0	human JJ B-adj.all	plasma NN B-noun.substance	( ( 0	in IN 0	vitro NN B-noun.location	) ) 0	, , 0	the DT 0	plasma NN B-noun.plant	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	nicardipine_HCl NNP B-noun.person	was VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d501.s10	In IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	evaluating VBG B-verb.change	the DT 0	minimum JJ B-adj.all	inhibitory JJ B-adj.all	concentration NN B-noun.cognition	( ( 0	MIC NNP 0	) ) 0	of IN 0	vancomycin NN B-noun.food	, , 0	cefazolin NN B-noun.body	, , 0	ampicillin NN B-noun.person	, , 0	ampicillin VB B-verb.change	/ JJ 0	flucoxacillin NN B-noun.substance	, , 0	ceftazidime NN B-noun.person	, , 0	gentamicin NN B-noun.person	, , 0	and CC 0	amphotericin NN B-noun.person	demonstrated VBD B-verb.perception	no DT 0	evidence NN B-noun.attribute	of IN 0	incompatibility NN B-noun.quantity	of IN 0	these DT 0	antibiotics NNS B-noun.person	with IN 0	EXTRANEAL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d97.s68	clarithromycin NN B-adj.all	concentration NN B-noun.event	__ ) 0	indinavir NN B-noun.phenomenon	concentration NN B-noun.event	. . 0
DDI-DrugBank.d234.s9	Use NN 0	in IN 0	Ambulatory NNP B-noun.other	Patients NNPS I-noun.other	The DT I-noun.other	effects NNS B-noun.phenomenon	of IN 0	ROMAZICON NNP B-noun.group	may MD 0	wear VB B-verb.body	off RP 0	before IN 0	a DT 0	long JJ B-noun.body	- : 0	acting_benzodiazepine NN B-noun.person	is VBZ B-verb.stative	completely RB B-adv.all	cleared VBN B-verb.change	from IN 0	the DT 0	body NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d124.s14	Antiarrhythmics NNS B-noun.person	, , 0	Amiodarone NNP B-noun.person	, , 0	bepridil NN B-noun.person	, , 0	flecainide NN 0	, , 0	propafenone NN B-noun.person	, , 0	quinidine RB B-adv.all	CONTRAINDICATED VBN B-verb.possession	due JJ 0	to TO 0	potential JJ B-adj.all	for IN 0	serious JJ B-adj.all	and/or NN B-noun.attribute	life NN I-noun.attribute	- : 0	threatening JJ B-verb.communication	reactions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d3.s18	Antiepileptic_Drugs NNS B-noun.artifact	, , 0	Sporadic JJ B-adj.all	cases NNS B-noun.event	of IN 0	seizures NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	during IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	TORADOL NNP B-noun.person	and CC 0	antiepileptic_drugs NNS B-noun.object	( ( 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d488.s4	Thus RB 0	in IN 0	order NN 0	to TO 0	avoid VB B-verb.social	bleeding NN B-verb.body	, , 0	reduced VBD B-verb.change	dosage NN B-noun.quantity	of IN 0	heparin NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	during IN 0	treatment NN B-noun.plant	with IN 0	antithrombin_III NNP B-noun.person	( ( 0	human JJ B-adj.all	) ) 0	. . 0	. . 0
DDI-MedLine.d40.s1	The DT 0	antifungal_drug NN B-noun.attribute	, , 0	miconazole_nitrate NNP B-noun.person	, , 0	inhibits VBZ B-verb.stative	the DT 0	growth NN 0	of IN 0	several JJ B-adj.all	species NNS B-noun.event	of IN 0	Candida NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d217.s3	Elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	cyclosporine NN B-noun.person	with IN 0	norfloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d334.s0	Hypotension NN B-noun.person	; : 0	Patients NNS B-noun.person	on IN 0	Diuretic NNP B-noun.person	Therapy NNP I-noun.person	, , 0	Patients NNPS B-noun.person	on IN 0	diuretics NNS B-noun.person	, , 0	and CC 0	especially RB B-adv.all	those DT 0	in IN 0	whom WP 0	diuretic JJ B-adj.all	therapy NN B-noun.act	was VBD B-verb.stative	recently RB B-adv.all	instituted VBN B-verb.communication	, , 0	may MD 0	occasionally RB 0	experience VB B-verb.social	an DT 0	excessive JJ B-adj.all	reduction NN B-noun.process	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	after IN 0	initiation NN B-noun.time	of IN 0	therapy NN 0	with IN 0	PRINIVIL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d137.s1	Sublingual JJ B-adj.all	nitroglycerin NN B-noun.person	may MD 0	be VB 0	taken VBN B-verb.communication	if IN 0	necessary JJ B-adj.all	for IN 0	the DT 0	control NN B-noun.act	of IN 0	acute JJ B-adj.all	angina NN 0	attacks NNS 0	during IN 0	Bepridil NNP B-noun.person	therapy NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d395.s0	Bismuth NNP B-noun.person	, , 0	Bismuth_subsalicylate JJ B-adj.all	, , 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	enoxacin NN B-noun.person	or CC 0	60 CD B-adj.all	minutes NNS B-noun.time	following VBG B-verb.stative	enoxacin JJ B-adj.all	administration NN B-noun.person	, , 0	decreased VBD B-verb.change	enoxacin JJ B-adj.all	bioavailability NN B-noun.cognition	by IN 0	approximately RB B-noun.time	25 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d526.s15	Monitor NNP B-noun.person	salicylate NN I-noun.person	levels NNS B-noun.state	or CC 0	the DT 0	therapeutic JJ B-adj.all	effect NN B-noun.cognition	for IN 0	which WDT 0	aspirin NN B-noun.attribute	is VBZ 0	given VBN B-verb.possession	, , 0	. . 0
DDI-DrugBank.d277.s3	GABITRIL NNP B-noun.group	is VBZ 0	considered VBN B-verb.cognition	to TO 0	be VB B-verb.stative	a DT 0	non NN B-noun.person	- : 0	enzyme NN B-noun.person	inducing VBG B-verb.body	AED NNP I-verb.body	. . 0	. . 0
DDI-DrugBank.d415.s9	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	random JJ B-noun.artifact	observations NNS I-noun.artifact	, , 0	have VBP 0	shown VBN B-verb.cognition	that DT 0	ibuprofen NN B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d49.s1	The DT 0	minimal JJ B-adj.all	inhibitory JJ B-noun.body	concentrations NNS I-noun.body	of IN 0	clindamycin NN B-noun.person	and CC 0	gentamicin VB B-verb.competition	alone RB I-verb.competition	and CC 0	in IN 0	combinations NNS B-noun.artifact	were VBD 0	determined VBN B-verb.communication	by IN 0	a DT 0	microdilution NN B-noun.time	method NN B-noun.attribute	for IN 0	163 CD 0	aerobic JJ B-adj.all	, , 0	facultative JJ 0	, , 0	and CC 0	anaerobic JJ B-adj.all	clinical JJ B-adj.all	isolates NNS B-noun.feeling	. . 0	. . 0
DDI-DrugBank.d397.s13	There EX 0	have VBP 0	been VBN 0	postmarketing VBG B-verb.communication	reports NNS B-noun.communication	of IN 0	drug NN B-noun.act	interactions NNS I-noun.act	when WRB 0	erythromycin NN B-noun.person	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	cisapride NN B-noun.food	, , 0	resulting VBG B-verb.stative	in IN 0	QT NNP 0	prolongation NN 0	, , 0	cardiac JJ B-adj.all	arrythmias NNS B-noun.person	, , 0	ventricular JJ B-adj.all	tachycardia NN B-noun.location	, , 0	ventricular JJ B-adj.all	fibrulation NN B-noun.act	, , 0	and CC 0	torsades VBZ B-verb.motion	de IN 0	pointes NNS B-noun.time	, , 0	most RBS 0	like IN 0	due JJ 0	to TO 0	inhibition NN B-noun.attribute	of IN 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.act	by IN 0	erythromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d362.s2	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	demonstrated VBD B-verb.cognition	that IN 0	the DT 0	plasma NN B-noun.plant	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	des NNS B-noun.person	- : 0	ciclesonide NN B-noun.person	was VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	warfarin NN B-noun.act	or CC 0	salicylic_acid JJ B-noun.substance	, , 0	indicating VBG B-verb.communication	no DT 0	potential NN B-noun.person	for IN 0	protein NN B-noun.substance	binding JJ B-verb.contact	- : 0	based VBN B-verb.cognition	drug NN B-noun.person	interactions NNS I-noun.person	. . 0	. . 0
DDI-MedLine.d16.s5	The DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	ketamine NN B-noun.person	in IN 0	plasma NN B-noun.substance	and CC 0	brain NN B-noun.person	was VBD B-verb.stative	longer RBR B-adv.all	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	halothane NN B-noun.person	than IN 0	when WRB 0	ketamine NN B-noun.person	was VBD 0	given VBN B-verb.possession	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d320.s1	In IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	indicate VBP B-verb.stative	CYP3A4 JJ B-adj.all	isoform NN B-noun.attribute	and CC 0	CYP1A2 JJ B-adj.all	isoform NN B-noun.body	mediate VB B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	levobupivacaine NN B-noun.attribute	to TO 0	desbutyl_levobupivacaine VB B-verb.motion	and CC 0	3-hydroxy_levobupivacaine JJ 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d350.s8	CANCIDAS NNP B-noun.group	did VBD 0	not RB B-adv.all	increase VB B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d177.s1	Consequently RB B-adv.all	, , 0	drugs NNS B-noun.person	with IN 0	a DT 0	low JJ B-adj.all	therapeutic JJ B-adj.all	margin NN B-noun.person	, , 0	such JJ 0	as IN 0	vitamin_K_antagonists NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	and CC 0	theophylline PRP 0	, , 0	could MD 0	have VB B-verb.perception	a DT 0	delayed JJ B-adj.all	elimination NN B-noun.person	and CC 0	increases NNS B-noun.event	in IN 0	their PRP$ 0	serum NN B-noun.body	half NN B-noun.attribute	- : 0	life NN B-noun.time	leading VBG B-verb.stative	to TO 0	a DT 0	toxic JJ B-adj.all	level NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d196.s41	PEGASYS NNP B-noun.group	and CC 0	COPEGUS NNP B-noun.group	are VBP 0	excreted VBN B-verb.stative	by IN 0	the DT 0	kidney NN B-noun.person	, , 0	and CC 0	the DT 0	risk NN 0	of IN 0	toxic JJ B-adj.all	reactions NNS B-noun.motive	to TO 0	this DT 0	therapy NN B-noun.act	may MD 0	be VB B-verb.stative	greater JJR B-adj.all	in IN 0	patients NNS B-noun.person	with IN 0	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d138.s0	Although IN 0	specific JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	conducted VBN B-verb.creation	with IN 0	ALPHAGAN_P NNP B-noun.person	, , 0	the DT 0	possibility NN B-noun.state	of IN 0	an DT 0	additive JJ B-adj.all	or CC 0	potentiating VBG B-verb.motion	effect NN 0	with IN 0	CNS_depressants NNS B-noun.person	( ( 0	alcohol NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	opiates NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	or CC 0	anesthetics NNS B-noun.body	) ) 0	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d32.s3	The DT 0	effect NN B-noun.cognition	of IN 0	ceftibuten NN B-noun.animal	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	theophylline PRP 0	administered VBD B-verb.body	orally RB I-verb.body	has VBZ 0	not RB 0	been VBN 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d112.s0	Effect NN 0	of IN 0	dofetillide NN 0	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d124.s17	Antimycobacterial_Agents NNS B-noun.artifact	, , 0	rifampin VB 0	CONTRAINDICATED NNP B-noun.group	since IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	this DT 0	product NN B-noun.cognition	with IN 0	saquinavir NN B-noun.person	in IN 0	an DT 0	antiretroviral JJ B-adj.all	regimen NNS B-noun.person	reduces VBZ B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	saquinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d382.s11	The DT 0	daily JJ B-noun.event	dose NN 0	of IN 0	dexamethasone NN 0	administered VBN B-verb.possession	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	with IN 0	Aprepitant NNP B-noun.person	reflects VBZ B-verb.cognition	an DT 0	approximate JJ B-noun.communication	50 CD B-adj.all	% NN 0	reduction NN B-noun.act	of IN 0	the DT 0	dose NN B-noun.quantity	of IN 0	dexamethasone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s38	This DT 0	was VBD 0	expected VBN B-verb.cognition	because IN 0	zaleplon NN B-noun.person	is VBZ B-verb.stative	primarily RB B-adv.all	metabolized VBN B-verb.change	and CC 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	unchanged JJ B-adj.all	zaleplon NN B-noun.person	accounts NNS B-noun.person	for IN 0	less JJR 0	than IN 0	1 CD B-adj.all	% NN 0	of IN 0	the DT 0	administered VBN B-verb.emotion	dose NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d74.s2	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	during IN 0	the DT 0	administration NN B-noun.time	of IN 0	adrenaline NN B-noun.person	to TO 0	patients NNS B-noun.person	anaesthetised VBD B-verb.communication	with IN 0	FLUOTHANE NNP 0	as IN 0	arrhythmias NNS B-noun.person	may MD 0	be VB 0	precipitated VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d97.s72	Use VB B-verb.consumption	lowest JJS B-adj.all	possible JJ B-adj.all	dose NN B-noun.quantity	of IN 0	atorvastatin NN B-noun.food	with IN 0	careful JJ B-adj.all	monitoring NN B-noun.person	, , 0	or CC 0	consider VB B-verb.communication	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	that WDT 0	are VBP B-verb.stative	not RB B-adv.all	primarily RB B-adv.all	metabolized VBN B-verb.social	by IN 0	CYP3A4 NNP B-noun.person	, , 0	such JJ 0	as IN 0	pravastatin NN B-noun.person	, , 0	fluvastatin NN B-noun.substance	, , 0	or CC 0	rosuvastatin NN B-noun.substance	in IN 0	combination NN 0	with IN 0	CRIXIVAN NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d22.s2	By IN 0	contrast NN 0	, , 0	spermidine NN B-noun.person	( ( 0	1 CD B-adj.all	mM CD B-noun.quantity	) ) 0	and CC 0	putrescine NN B-noun.person	( ( 0	1 CD B-adj.all	mM CD B-noun.quantity	) ) 0	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	translocation NN B-noun.communication	when WRB 0	added VBN B-verb.communication	alone RB 0	. . 0	. . 0
DDI-DrugBank.d406.s0	May MD 0	interact VB B-verb.change	with IN 0	cefamandole_naftate NNP B-noun.location	, , 0	cephalothin_sodium NN 0	, , 0	magnesium_sulfate JJ B-noun.person	, , 0	prednisolone_sodium_succinate JJ B-adj.all	, , 0	and CC 0	prochlorperazine_edisylate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d307.s3	Results NNS B-noun.other	demonstrate VBP B-verb.communication	that IN 0	oxcarbazepine NN B-noun.person	and CC 0	its PRP$ 0	pharmacologically RB B-adv.all	active JJ B-adj.all	10-monohydroxy JJ B-adj.all	metabolite NN B-noun.attribute	( ( 0	MHD NNP 0	) ) 0	have VBP B-verb.stative	little JJ I-verb.stative	or CC 0	no DT 0	capacity NN B-noun.act	to TO 0	function VB B-verb.competition	as IN 0	inhibitors NNS B-noun.person	for IN 0	most JJS 0	of IN 0	the DT 0	human JJ B-adj.all	cytochrome NN B-noun.person	P450 NN I-noun.person	enzymes NNS B-noun.person	evaluated VBN B-verb.consumption	( ( 0	CYP1A2 NNP B-noun.person	, , 0	CYP2A6 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP2E1 NNP B-noun.person	, , 0	CYP4A9 NNP B-noun.group	and CC I-noun.group	CYP4A11 NNP I-noun.group	) ) 0	with IN 0	the DT 0	exception NN B-noun.act	of IN 0	CYP2C19 NNP B-noun.person	and CC 0	CYP3A4/5 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d551.s4	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	coadministration NN B-noun.person	of IN 0	WelChol NNP B-noun.person	_ CC 0	with IN 0	atorvastatin NN B-noun.food	, , 0	lovastatin NN B-noun.person	, , 0	or CC 0	simvastatin NN B-noun.attribute	did VBD 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	lipid NN B-noun.body	- : 0	lowering VBG B-verb.motion	activity NN B-noun.process	of IN 0	the DT 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitor NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d501.s7	Heparin NNP B-noun.person	, , 0	No DT 0	human JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	heparin NN B-noun.person	were VBD 0	conducted VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d478.s4	Selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	( ( 0	e.g. UH 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	, , 0	rarely RB B-adv.all	, , 0	to TO 0	cause VB B-verb.emotion	weakness NN I-verb.emotion	, , 0	hyperreflexia NN B-noun.person	, , 0	and CC 0	incoordination NN B-noun.time	when WRB 0	coadministered VBN B-verb.communication	with IN 0	5-HTv JJ 0	agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d274.s3	There EX 0	was VBD B-verb.stative	no DT 0	evidence NN B-noun.attribute	of IN 0	drug NN B-noun.person	interactions NNS I-noun.person	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	in IN 0	which WDT 0	dobutamine NN B-noun.person	was VBD 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.stative	digitalis_preparations NNS I-verb.stative	, , 0	furosemide RB 0	, , 0	spironolactone NN 0	, , 0	lidocaine NN B-noun.person	, , 0	glyceryl_trinitrate JJ B-adj.all	, , 0	isosorbide_dinitrate JJ B-adj.all	, , 0	morphine NN B-noun.person	, , 0	atropine NN B-noun.person	, , 0	heparin NN B-noun.person	, , 0	protamine NN B-noun.person	, , 0	potassium_chloride JJ 0	, , 0	folic_acid JJ 0	, , 0	and CC 0	acetaminophen NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d60.s5	Although IN 0	not RB B-adv.all	studied VBN B-verb.cognition	systematically RB B-adv.all	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	no DT 0	drug NN B-noun.person	interactions NNS I-noun.person	were VBD 0	observed VBN B-verb.perception	when WRB 0	vecuronium NN B-noun.person	, , 0	pancuronium NN B-noun.person	, , 0	or CC 0	atracurium NN B-noun.artifact	were VBD 0	administered VBN B-verb.possession	following VBG 0	varying VBG B-verb.change	degrees NNS B-noun.communication	of IN 0	recovery NN B-noun.process	from IN 0	single JJ B-adj.all	doses NNS B-noun.event	or CC 0	infusions NNS B-noun.cognition	of IN 0	NIMBEX NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d130.s3	To TO 0	determine VB B-verb.communication	whether IN 0	injection NN B-noun.act	of IN 0	thiosulfate NN B-noun.person	would MD 0	permit VB B-verb.change	larger JJR B-adj.all	doses NNS B-noun.person	of IN 0	cisplatin NN B-noun.person	to TO 0	be VB 0	administered VBN B-verb.possession	, , 0	a DT 0	fixed VBN B-verb.consumption	9.9-g NNP I-verb.consumption	/ : 0	m2 PRP$ 0	dose NN B-noun.quantity	of IN 0	thiosulfate NN B-noun.person	was VBD 0	given VBN B-verb.possession	intravenously RB B-adv.all	over IN 0	three CD 0	hours NNS 0	concurrently RB B-adv.all	with IN 0	escalating VBG B-verb.motion	doses NNS B-noun.act	of IN 0	cisplatin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d522.s21	Anticoagulants NNS B-noun.person	, , 0	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	increased VBN B-verb.change	anticoagulant JJ B-adj.all	effects NNS B-noun.phenomenon	when WRB 0	erythromycin NN B-noun.person	and CC 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	were VBD 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-MedLine.d120.s0	Molecular JJ B-adj.all	basis NN B-noun.cognition	for IN 0	the DT 0	selective JJ B-adj.all	toxicity NN B-noun.attribute	of IN 0	amphotericin_B NNP B-noun.person	for IN 0	yeast NN B-noun.time	and CC 0	filipin NN B-noun.person	for IN 0	animal NN B-noun.animal	cells NNS B-noun.body	. . 0	. . 0
DDI-MedLine.d63.s8	descending VBG B-verb.communication	epsilon NN B-noun.person	and CC 0	mu IN 0	systems NNS B-noun.food	for IN 0	beta JJ 0	- : 0	endorphin NN B-noun.person	and CC 0	morphine NN B-noun.person	, , 0	respectively RB B-adv.all	, , 0	are VBP 0	proposed VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d170.s7	MAO_Inhibitors NNS B-noun.person	, , 0	DURAGESIC NNP 0	_ , 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	for IN 0	use NN 0	in IN 0	patients NNS B-noun.person	who WP 0	have VBP 0	received VBN B-verb.possession	MAOI NNP B-noun.other	within IN 0	14 CD B-adj.all	days NNS B-noun.act	because RB 0	severe JJ 0	and CC 0	unpredictable JJ B-adj.all	potentiation NN B-noun.person	by IN 0	MAO_inhibitors NNS B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	opioid_analgesics NNS B-noun.person	. . 0
DDI-DrugBank.d536.s1	These DT 0	drugs NNS B-noun.artifact	include VBP B-verb.change	the DT 0	thiazides NNS B-noun.artifact	and CC 0	other JJ 0	diuretics NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	thyroid_products NNS B-noun.body	, , 0	estrogens VBZ B-verb.cognition	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	nicotinic_acid JJ 0	, , 0	sympathomimetics NNS B-noun.person	, , 0	calcium_channel NNS B-noun.person	- : 0	blocking_drugs NNS B-noun.time	, , 0	and CC 0	isoniazid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s24	Protease_inhibitor NN B-noun.person	, , 0	atazanavir NN B-noun.person	. . 0
DDI-DrugBank.d503.s3	Avoid VB B-verb.social	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	chlorprothixene NN B-noun.person	and CC 0	tramadol NN B-noun.person	( ( 0	Ultram NNP B-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d338.s8	The DT 0	following NN 0	are VBP B-verb.stative	examples NNS B-noun.cognition	of IN 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	other JJ 0	related JJ B-adj.all	benzodiazepines NNS B-noun.person	, , 0	presumably RB B-adv.all	through IN 0	inhibition NN B-noun.time	of IN 0	CYP3A NNP B-noun.person	, , 0	nefazodone NN 0	, , 0	fluvoxamine NN B-noun.person	, , 0	cimetidine NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	isoniazide NN 0	, , 0	and CC 0	some DT 0	macrolide_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s67	Should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	as IN 0	sole JJ B-adj.all	protease_inhibitor NN B-noun.person	in IN 0	combination NN 0	with IN 0	SUSTIVA NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d104.s8	In IN 0	order NN 0	to TO 0	examine VB B-verb.communication	some DT 0	molecular JJ B-adj.all	mechanisms NNS B-noun.person	of IN 0	PCP NNP B-noun.group	- : 0	induced VBN B-verb.creation	behavioral JJ B-noun.body	changes NNS I-noun.body	, , 0	Northern JJ B-adj.all	blot NN B-noun.person	analysis NN 0	of IN 0	total JJ B-adj.all	RNA NNP 0	from IN 0	prefrontal JJ B-adj.all	cortical JJ B-adj.all	tissues NNS B-noun.event	of IN 0	mice NNS B-noun.person	treated VBN B-verb.change	with IN 0	PCP NNP B-noun.group	, , 0	DCG NNP B-noun.group	- : 0	IV NNP 0	, , 0	and CC 0	L NNP 0	- : 0	CCG-1 NN B-noun.other	was VBD 0	carried VBN B-verb.change	out RP I-verb.change	. . 0	. . 0
DDI-DrugBank.d143.s38	The DT 0	continued JJ B-adj.all	need NN B-noun.motive	for IN 0	the DT 0	other JJ 0	antiarrhythmic JJ B-adj.all	agent NN B-noun.person	should MD 0	be VB 0	reviewed VBN B-verb.change	after IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	amiodarone NN 0	have VBP 0	been VBN 0	established VBN B-verb.creation	, , 0	and CC 0	discontinuation NN B-noun.person	ordinarily RB 0	should MD 0	be VB 0	attempted VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d562.s3	Quinolones NNS B-noun.communication	have VBP 0	also RB B-adv.all	been VBN 0	shown VBN B-verb.perception	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	caffeine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d415.s15	Thus RB 0	, , 0	when WRB 0	ibuprofen NNS B-noun.person	and CC 0	lithium NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	, , 0	subjects NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	carefully RB B-adv.all	for IN 0	signs NNS B-noun.communication	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d89.s1	Gentamicin NNP B-noun.person	is VBZ B-verb.stative	an DT 0	aminoglycoside_antibiotic JJ B-adj.all	used VBN B-verb.consumption	to TO 0	treat VB B-verb.body	a DT 0	wide JJ B-adj.all	variety NN B-noun.attribute	of IN 0	infections NNS B-noun.phenomenon	caused VBN B-verb.communication	by IN 0	gram NN B-noun.person	- : 0	negative JJ B-adj.all	organisms NNS B-noun.Tops	, , 0	but CC 0	it PRP 0	is VBZ B-verb.stative	potentially RB B-adj.all	toxic JJ B-adj.all	to TO 0	the DT 0	kidneys NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d522.s7	The DT 0	mean JJ B-adj.all	QT NNP 0	c , 0	interval NN B-noun.cognition	( ( 0	msec NN 0	) ) 0	was VBD B-verb.stative	369 CD 0	with IN 0	terfenadine NN 0	alone RB 0	and CC 0	367 CD 0	with IN 0	terfenadine NN B-noun.person	plus CC 0	dirithromycin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d246.s11	Conversely RB B-adv.all	, , 0	the DT 0	administration NN B-noun.time	of IN 0	STADOL_NS NNS B-noun.phenomenon	( ( 0	1 CD 0	mg NN 0	butorphanol NN 0	QID NNP 0	) ) 0	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	a DT 0	300-mg JJ 0	dose NN B-noun.quantity	of IN 0	cimetidine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d412.s11	Care NN B-noun.group	should MD 0	be VB 0	taken VBN B-verb.communication	if IN 0	labetalol NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	calcium_antagonists NNS B-noun.person	of IN 0	the DT 0	verapamil NN B-noun.artifact	type NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d22.s2	Aminosalicylic_acid JJ B-noun.possession	may MD 0	also RB 0	decrease VB B-verb.communication	the DT 0	absorption NN B-noun.artifact	of IN 0	vitamin_B12 NNP B-noun.location	, , 0	which WDT 0	can MD 0	lead VB B-verb.cognition	to TO 0	a DT 0	deficiency NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d437.s14	Appropriate JJ B-adj.all	laboratory NN B-noun.act	testing NN B-verb.social	should MD 0	be VB 0	considered VBN B-verb.cognition	prior RB 0	to TO 0	initiating VBG B-verb.emotion	combination NN I-verb.emotion	therapy NN 0	with IN 0	Amprenavir NNP B-noun.person	and CC 0	ritonavir NN B-noun.person	and CC 0	at IN 0	periodic JJ B-noun.cognition	intervals NNS I-noun.cognition	or CC 0	if IN 0	any DT 0	clinical JJ B-adj.all	signs NNS B-noun.communication	or CC 0	symptoms NNS B-noun.communication	of IN 0	hyperlipidemia NN B-noun.state	or CC 0	elevated JJ B-adj.all	liver NN B-noun.person	function NN B-noun.act	tests NNS B-noun.cognition	occur VBP 0	during IN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d329.s3	Because IN 0	of IN 0	the DT 0	small JJ B-adj.all	effect NN 0	on IN 0	half NN B-noun.person	- : 0	life NN B-noun.time	, , 0	the DT 0	coadministration NN B-noun.person	with IN 0	probenecid NN B-noun.person	to TO 0	extend VB B-verb.stative	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	ertapenem NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d223.s24	Additionally RB B-adv.all	, , 0	higher JJR B-adj.all	than IN 0	expected VBN B-verb.cognition	tricyclic_antidepressant JJ B-adj.all	levels NNS B-noun.attribute	have VBP 0	been VBN 0	observed VBN B-verb.perception	when WRB 0	they PRP 0	are VBP 0	begun VBN B-verb.change	in IN 0	patients NNS B-noun.location	already RB B-adv.all	taking VBG B-verb.competition	cimetidine NN I-verb.competition	. . 0	. . 0
DDI-DrugBank.d247.s1	All DT 0	vasopressors NNS B-noun.object	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d536.s3	When WRB 0	such JJ B-adj.all	drugs NNS B-noun.artifact	are VBP 0	withdrawn VBN B-verb.contact	from IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	Acarbose NNP B-noun.person	in IN 0	combination NN 0	with IN 0	sulfonylureas NNS B-noun.artifact	or CC 0	insulin NN B-noun.substance	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	any DT 0	evidence NN B-noun.attribute	of IN 0	hypoglycemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d137.s4	Digoxin NNP B-noun.person	, , 0	In IN 0	controlled JJ B-adj.all	studies NNS B-noun.group	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	bepridil_hydrochloride IN 0	either CC 0	had VBD 0	no DT 0	effect NN B-noun.cognition	( ( 0	one CD 0	study NN B-noun.artifact	) ) 0	or CC 0	was VBD 0	associated VBN B-verb.cognition	with IN 0	modest JJ B-adj.all	increases NNS B-noun.event	, , 0	about IN 0	30 CD B-adj.all	% NN 0	( ( 0	two CD 0	studies NNS B-noun.group	) ) 0	in IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	serum NN B-noun.body	digoxin NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d507.s8	Anticoagulants NNS B-noun.person	, , 0	Ten CD 0	patients NNS B-noun.person	who WP 0	were VBD 0	stabilized VBN B-verb.consumption	on IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	were VBD 0	given VBN B-verb.possession	guanfacine NN 0	, , 0	1 CD B-adj.all	- : 0	2 CD 0	mg RB 0	/ JJ 0	day NN 0	, , 0	for IN 0	4 CD B-adj.all	weeks NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d46.s14	There EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	changes NNS B-noun.relation	in IN 0	corrected VBN B-verb.change	QT NNP 0	intervals NNS 0	during IN 0	administration NN B-noun.time	of IN 0	cisapride NN B-noun.phenomenon	alone RB B-adv.all	or CC 0	with IN 0	fluoxetine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d284.s4	The DT 0	ECG NNP 0	changes NNS B-noun.artifact	and/or CC 0	hypokalemia NN B-noun.attribute	that WDT 0	may MD 0	result VB B-verb.stative	from IN 0	the DT 0	administration NN B-noun.time	of IN 0	non NN B-noun.person	- : 0	potassium_sparing_diuretics NNS B-noun.person	( ( 0	such JJ 0	as IN 0	loop NN 0	or CC 0	thiazide_diuretics NNS B-noun.artifact	) ) 0	can MD 0	be VB B-verb.stative	acutely RB B-adv.all	worsened VBN B-verb.social	by IN 0	beta NNS B-noun.person	- : 0	agonists NNS B-noun.person	, , 0	especially RB B-adv.all	when WRB 0	the DT 0	recommended VBN B-verb.communication	dose NN B-noun.quantity	of IN 0	the DT 0	beta NN B-noun.body	- : 0	agonist NN B-noun.person	is VBZ 0	exceeded VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d54.s21	Vasopressors NNS B-noun.person	, , 0	Thyroxine NNP B-noun.person	increases VBZ B-verb.change	the DT 0	adrenergic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	catecholamines NNS B-noun.animal	such JJ 0	as IN 0	epinephrine NN B-noun.person	and CC 0	norepinephrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d526.s24	When WRB 0	estrogen NN 0	therapy NN 0	is VBZ 0	initiated VBN B-verb.creation	, , 0	a DT 0	reduction NN B-noun.act	in IN 0	corticosteroid JJ B-adj.all	dosage NN B-noun.quantity	may MD 0	be VB 0	required VBN B-verb.stative	, , 0	and CC 0	increased VBD B-verb.change	amounts NNS B-noun.artifact	may MD 0	be VB 0	required VBN B-verb.stative	when WRB 0	estrogen NN B-noun.animal	is VBZ 0	terminated VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d110.s8	Both DT 0	ibogaine NN B-noun.person	and CC 0	18-MC JJ 0	enhance NN B-noun.phenomenon	the DT 0	locomotor NN B-noun.location	and/or CC 0	stereotypic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	stimulants NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d382.s5	Coadministration NN B-noun.person	of IN 0	Aprepitant NNP B-noun.person	with IN 0	these DT 0	drugs NNS B-noun.artifact	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	known VBN B-verb.cognition	to TO 0	be VB 0	metabolized VBN B-verb.cognition	by IN 0	CYP2C9 NNP B-noun.person	, , 0	such JJ 0	as IN 0	phenytoin NN B-noun.person	, , 0	may MD 0	result VB B-verb.stative	in IN 0	lower JJR B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d82.s26	INDOCIN NNP 0	reduces VBZ B-verb.stative	basal NN B-adj.all	plasma NN B-noun.plant	renin NN B-noun.body	activity NN B-noun.process	( ( 0	PRA NNP 0	) ) 0	, , 0	as RB 0	well RB 0	as IN 0	those DT 0	elevations NNS B-noun.cognition	of IN 0	PRA NNP B-noun.group	induced VBN B-verb.creation	by IN 0	furosemide JJ B-adj.all	administration NN B-noun.person	, , 0	or CC 0	salt NN B-noun.act	or CC 0	volume NN B-noun.artifact	depletion NN B-noun.act	. . 0	. . 0
